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 Coxsackievirus B3 (CVB), an enterovirus, is a small, ssRNA virus with a genome of 
approximately 7 kB. There are 2 million symptomatic CVB infections annually in the United 
States, ranging from mild febrile illnesses to myocarditis, meningoencephalitis, or pancreatitis. 
CVB is a fecal-oral pathogen and must overcome diverse cellular barriers to cause disease, 
including the polarized epithelium lining the gastrointestinal tract. Viral infection of a host cell 
results in a variety of cellular responses that serve to control the viral infection. Once such 
response is the activation of intracellular innate immune signaling; this results in the production 
of type I interferon, which signals in an auto- and paracrine fashion to alter the transcriptional 
profile of a cell to inhibit viral replication. A second response to viral infection is the induction 
of cell death pathways; as viruses utilize host cell machinery for replication, early cell death of a 
host cell can result in an abortive infection. Here, I examine the ways in which CVB interfaces 
with these host cell pathways that affect viral replication. A primary mechanism utilized by CVB 
for altering host cell pathways is the production of the virally-encoded cysteine protease 3Cpro. 
3Cpro is required to process the viral polypeptide but is also known to target cellular protein 
targets for proteolysis. Here, I identify two cellular proteins targeted for proteolysis by 3Cpro, 
Unc93b and RIP3, that are involved in the intracellular innate immune signaling and cell death 
pathways, respectively. I then characterize the roles of these proteins and their cleavage during 
CVB infection. In summary, I explore the ways in which CVB manipulates its host cell through 
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proteolysis of host cell proteins by the virally-encoded protease 3Cpro and find that the balance 
between virus and host is finely tuned through the activity of this protease. 
 v 
TABLE OF CONTENTS 
PREFACE .................................................................................................................................... XI 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 COXSACKIEVIRUS B3 ..................................................................................... 1 
1.1.1 Pathogenesis of CVB ....................................................................................... 1 
1.1.1.1 History of CVB Pathogenesis ............................................................... 1 
1.1.1.2 Route of CVB Infection ........................................................................ 3 
1.1.1.3 CVB infection of the heart .................................................................... 4 
1.1.1.4 CVB infection of the central nervous system ...................................... 6 
1.1.1.5 CVB infection of the pancreas ............................................................. 6 
1.1.2 Viral Life Cycle ................................................................................................ 7 
1.1.2.1 Viral Entry ............................................................................................. 8 
1.1.2.2 Viral Replication ................................................................................... 9 
1.1.2.3 Viral Egress ......................................................................................... 10 
1.2 CVB INFECTION AND CELL DEATH ........................................................ 11 
1.2.1 CVB-Induced Apoptosis ............................................................................... 13 
1.2.2 CVB-Induced Necrosis .................................................................................. 15 
1.3 CVB INFECTION AND INNATE IMMUNE SIGNALING ......................... 16 
1.3.1 TLR-mediated CVB sensing ......................................................................... 18 
 vi 
1.3.2 RLR-mediated CVB sensing ......................................................................... 20 
1.4 VIRUS-HOST CELL INTERACTIONS DURING CVB INFECTION ...... 21 
1.4.1 CVB and host cell translation ....................................................................... 21 
1.4.2 CVB and cell death signaling ........................................................................ 22 
1.4.3 CVB and innate immune signaling .............................................................. 23 
1.5 UNC93B AND TOLL-LIKE RECEPTOR TRAFFICKING ........................ 24 
1.6 RIP3-DEPENDENT NECROPTOSIS ............................................................. 26 
1.6.1 Cellular mechanisms of necroptosis ............................................................. 27 
1.6.1.1 Activation of necroptosis .................................................................... 27 
1.6.1.2 Negative regulation of necroptosis ..................................................... 29 
1.6.1.3 Necroptosis signaling .......................................................................... 31 
1.6.1.4 Necroptosis effector mechanisms ....................................................... 32 
1.6.2 Necroptosis and microbial infections ........................................................... 34 
1.6.3 Necroptosis in human physiology ................................................................. 36 
1.7 AUTOPHAGY ................................................................................................... 37 
1.7.1 Mechanisms of Autophagy ............................................................................ 38 
1.7.2 Autophagy and CVB infection ..................................................................... 40 
2.0 UNC93B INDUCES CELL DEATH AND IS CLEAVED BY CASPASES AND 
AN ENTEROVIRAL PROTEASE ........................................................................................... 42 
2.1 INTRODUCTION ............................................................................................. 42 
2.2 RESULTS ........................................................................................................... 45 
2.2.1 Expression of Unc93b induces cell death ..................................................... 45 
2.2.2 Unc93b is cleaved by caspases ...................................................................... 48 
 vii 
2.2.3 Unc93b is cleaved by the CVB virally-encoded protease 3Cpro ................. 50 
2.2.4 Unc93b cleavage does not effect its localization or trafficking .................. 54 
2.2.5 Unc93b cleavage does not effect its induction of cell death. ...................... 56 
2.3 DISCUSSION ..................................................................................................... 58 
3.0 RIP3 IS REQUIRED FOR CVB INFECTION ....................................................... 61 
3.1 INTRODUCTION ............................................................................................. 61 
3.2 RESULTS ........................................................................................................... 64 
3.2.1 RIP3 facilitates CVB infection in intestinal epithelial cells ....................... 64 
3.2.2 RIP3 silencing reduces CVB replication prior to viral egress ................... 67 
3.2.3 RIP3 is not required for CVB entry into intestinal epithelial cells ........... 68 
3.2.4 RIP3 regulates autophagy in intestinal epithelial cells .............................. 69 
3.2.5 RIP3 interacts with p62 ................................................................................. 73 
3.2.6 The CVB-encoded cysteine protease 3Cpro cleaves RIP3 ........................... 74 
3.2.7 3Cpro-mediated cleavage fragments are incapable of inducing necrotic cell 
death… ........................................................................................................................ 77 
3.2.8 The C-terminal fragment of RIP3 generated by 3Cpro cleavage retains its 
ability to bind p62 ...................................................................................................... 78 
3.3 DISCUSSION ..................................................................................................... 81 
4.0 CONCLUSIONS ........................................................................................................ 87 
4.1 UNC93B AND CELL DEATH ......................................................................... 88 
4.2 RIP3 AND CVB INFECTION .......................................................................... 88 
4.3 CONCLUDING REMARKS ............................................................................ 89 
5.0 MATERIALS AND METHODS .............................................................................. 90 
 viii 
APPENDIX A ............................................................................................................................ 100 
APPENDIX B ............................................................................................................................ 104 
BIBLIOGRAPHY ..................................................................................................................... 107 
 ix 
 LIST OF TABLES 
 
Table 1. Virus-Host Cell Interactions ........................................................................................... 21 
 x 
LIST OF FIGURES 
Figure 1. CVB intestinal infection and dissemination. ................................................................... 4 
Figure 2. Polyprotein of CVB. ...................................................................................................... 10 
Figure 3. Cellular Mechanisms of Necroptosis ............................................................................. 34 
Figure 4.  Unc93b expression induces apoptotic cell death. ......................................................... 47 
Figure 5. Unc93b is cleaved by caspases during apoptosis. ......................................................... 50 
Figure 6. Unc93b is cleaved by 3Cpro during CVB infection. ...................................................... 53 
Figure 7. Unc93b cleavage does not affect trafficking to endosomes. ......................................... 55 
Figure 8.  Unc93b cleavage does not affect its induction of cell death. ....................................... 57 
Figure 9. RIP3 facilitates CVB Infection in intestinal epithelial cells. ......................................... 66 
Figure 10. RIP3 silencing restricts CVB replication prior to viral egress but is not required for 
viral entry. ..................................................................................................................................... 69 
Figure 11. RIP3 is required for autophagic flux in intestinal epithelial cells. .............................. 72 
Figure 12. RIP3 associates with p62. ............................................................................................ 74 
Figure 13. The CVB-encoded cysteine protease 3Cpro cleaves RIP3 ........................................... 76 
Figure 14. 3Cpro-mediated cleavage of RIP3 alters host cell signaling pathways. ....................... 81 
Figure 15. Schematic depicting the role of RIP3 during CVB infection. ..................................... 82 
Figure 16. RIP3 residue Q430 is conserved in the common ancestor of the apes. ....................... 86 
 xi 
PREFACE 
This work would not have been possible without the support of many people and organizations. 
I’d like to thank Carolyn for acting as my mentor in every sense of the word – for being an 
incredible example of a scientist driven by curiosity, for copious amounts of advice and 
encouragement, and for always reminding me to ‘enjoy my youth’. I’m also very grateful to the 
rest of the members of the Coyne lab, past and present. You people are fun to be around, you’re 
fun to talk science with, and you’re always there to help me out when I need an extra hand, to 
bounce an idea off someone, or help finding something I’ve lost deep in the recesses of the -80. 
 I’d also like to thank the other members of my thesis committee – Jen, Saumen, Sarah, 
and Jian, for their support. My committee meetings were always positive experiences and after 
each one I came away with new perspective on my project and new ideas for surmounting 
experimental and theoretical obstacles. Thanks for shepherding me through this process. 
Additionally, I’d like to thank the funding sources that have made this work possible – 
the NIAID and the Burroughs Wellcome fund. I’d also like to thank the ARCS Foundation, 
Pittsburgh chapter, particularly the three couples who funded my scholarship through that 
foundation – to Charlotte and Henry Beukema, Beth and Russ Wainwright, and Cynthia Carrow 
and Jim Kyper, thank you for your encouragement, your interest, and all the lovely food and 
conversation. 
 xii 
In addition, I’d like to thank those within the University of Pittsburgh and those outside 
of it who have provided support in the completion of this work. Drs. Saumen Sarkar, Donna 
Stolz, Joanne Flynn, and Neal DeLuca  (University of Pittsburgh), Dr. Xiaodong Wang (UTSW 
and NIBS), Drs. Cheryl Nickerson and Shameema Sarkar (Arizona State University), Drs. 
Harmit Malik and Maulik Patel (Fred Hutchinson Cancer Research Center), Drs. Sara Cherry 
and Jeff Bergelson (University of Pennsylvania), Dr. William Humphries (B&B microscopes), 
JoAnn Polk, John Viaropulos, Mary Lou Meyer, and Kristin DiGiacomo (University of 
Pittsburgh).  
Finally, I’d like to thank my family and friends. To my parents, Mark and Lisa, you two 
are the best support system I’ve ever encountered. Thanks for your cards, visits, and unflagging 
confidence and thanks for always being a safe spot to land. To my brother, Sam, you are possibly 
the wisest brother anyone has ever had; you make me better and I’m grateful. To my partner, 
Allen, thanks for being genuinely interested in my work, even the boring parts, and being 
everlastingly patient when I claim an experiment will only take me 5 more minutes. I’m also 
endlessly grateful to my community of people at home in Indiana and here in Pittsburgh. There 
are too many kind people and kind actions to list here, but I’m overwhelmed when I think about 
all the love that has come my way while I’ve been working on this project. 
  1 
1.0  INTRODUCTION 
1.1 COXSACKIEVIRUS B3 
1.1.1 Pathogenesis of CVB 
Coxsackievirus B3 (CVB) is a non-enveloped virus in the enterovirus genus with a positive-
sense RNA genome 7 kB in length. Enteroviruses are the most common human viral pathogens 
[1, 2] and cause a diverse range of diseases. Here, the pathogenesis of CVB is discussed. 
1.1.1.1 History of CVB Pathogenesis. Originally isolated in Coxsackie, New York in 1947 [3], 
investigation into coxsackieviruses began in the context of the public health fight against 
epidemics of poliomyelitis. Non-paralytic poliomyelitis is characterized by an aseptic meningitis, 
in which the meninges become inflamed without evidence of a bacterial infection. A subset of 
cases progress to paralytic poliomyelitis, which is marked by destruction of motor neurons in the 
anterior horn of the spinal cord and subsequent flaccid paralysis.  
In the 1800s, physicians began assembling detailed case studies of flaccid paralysis 
cases[4-6]; observations of the destruction of the gray matter of the spinal cord in these cases led 
to adoption of the name poliomyelitis (from the Greek for gray, polios). Though it had been 
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concluded based on epidemiological information that paralytic poliomyelitis was caused by an 
infectious agent [7, 8], in the early 1900s it was shown that spinal cord suspensions from patients 
who succumbed to paralytic poliomyelitis caused a paralytic disease in monkeys, that this 
disease was transmissible from monkey to monkey, and that the infectious agent was found in 
spinal cord suspensions from which bacteria and parasites had been removed [9, 10]. These 
observations led to the conclusion that the etiologic agent for poliomyelitis was a virus, 
subsequently dubbed poliovirus. By the 1940s, it was understood that poliovirus was transmitted 
primarily by a fecal-oral route, and techniques had been developed to isolate virus shed in the 
feces of patients [11].  
In 1947, two children in Coxsackie, New York, presented with poliomyelitis-like 
symptoms, but the virus isolated from their fecal samples was not poliovirus, as expected. This 
virus was not neutralized by serum targeting poliovirus and induced pathologies in animal 
models divergent from that seen with poliovirus [3]. Subsequent clinical isolations of several 
serologically distinct viruses with similar pathologies in animal models led to the establishment 
of a group of viruses known as coxsackieviruses [12]. By 1950, the coxsackieviruses had been 
divided into 2 groups, A and B, based on the pathology caused in a suckling mouse model of 
infection [13]. Individual strains within these groups were distinguished by their antigenic 
diversity [14], this nomenclature persists to the present. In 1957, the genus enterovirus was 
established to contain poliovirus, the coxsackieviruses, and another newly discovered group of 
viruses known as the enteric cytopathic human orphan (ECHO) viruses [15]. 
Researchers now turned their attention to establishing the role of coxsackieviruses in 
human disease. It was unclear at this point whether coxsackieviruses were the etiologic agents of 
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poliomyelitis-like symptoms in the patients from which they had been isolated, or whether the 
presence of coxsackievirus was incidental in these patients [16]. It was recognized that 
seroprevalance for antibodies directed against coxsackieviruses was high in the general 
population, without accompanying reports of major illness, indicating that many infections 
caused subclinical infection [17, 18]. However, through extensive clinical surveillance, it was 
determined that coxsackieviruses from group B, particularly Coxsackievirus B3 (here, CVB) 
were responsible for cases of aseptic meningitis, resembling non-paralytic poliomyelitis, as well 
as myocarditis in infants and adults [19, 20]. Though it was observed soon after discovery of 
coxsackieviruses that group B coxsackieviruses exhibited tropism for the pancreas in mouse 
models [21, 22], it was not until almost 20 years later that a correlation between antibodies to 
group B coxsackievirus and onset of type I diabetes was observed [23], leading to an active field 
of research describing the role of coxsackievirus infection in the destruction of pancreatic β cells 
and subsequent development of diabetes [24].  
The story of the discovery of coxsackieviruses is a lesson in the importance of careful 
observation in science. In seeking to isolate poliovirus, an entire group of viruses with a 
significant impact on human health were found, in an era before genetic techniques or even 
mammalian tissue culture were available for virus discovery work. The meticulous work that was 
undertaken to determine the role for coxsackieviruses in human disease inaugurated the modern 
field of coxsackievirus research. 
1.1.1.2 Route of CVB Infection. Much of the knowledge about how CVB enters the body and 
causes disease is derived from studies done with poliovirus. As detailed above, poliovirus is 
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spread through the fecal-oral route, and the initial isolation of CVB was made from fecal 
samples. If the intestinal epithelial barrier is breached, a primary viremia may result. This 
viremia appears before any major symptoms of disease, commonly occurs among infected 
individuals, and also can occur in abortive illnesses, those in which no serious symptoms ever 
result [25, 26]. A secondary or ‘major’ viremia occurs in a subset of people due to continued 
viral replication in secondary sites of infection [27]. It is upon this secondary viremia that the 
virus gains access to distal organs including the central nervous system (CNS), heart, and 
pancreas and causes disease in these organs (Figure 1), the pathogenesis of these diseases are 
detailed in the following sections. 
 
Figure 1. CVB intestinal infection and dissemination. 
CVB infects a new host through the fecal-oral route. After replicating in and breaching the GI tract (black line), a 
primary viremia may result. After this, a secondary major viremia may result due to continued viral replication in 
secondary sites of infection. This viremia can lead to infection of distal sites including the CNS, heart, or pancreas 
(red lines), where serious pathologies may occur. 
1.1.1.3 CVB infection of the heart. One of the most serious potential outcomes of a CVB 
infection is the dissemination of the virus to the heart and the subsequent development of 
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myocarditis, which can then further progress to dilated cardiomyopathy. These conditions are 
major causes of heart failure, particularly among children and adolescents [28]. Evidence of an 
enterovirus infection is found in up to 50% of cardiomyopathy cases [29-31]. CVB infections 
contribute to development of cardiomyopathy in two distinct ways—(1) the virus can directly 
infect and induce the cell death of cardiomyocytes or (2) they can trigger an autoimmune 
response in which the host’s own immune system destroys cardiomyocytes and leads to the 
characteristic inflammation seen in cardiomyopathy. CVB infection does indeed directly cause 
apoptosis of cardiomyocytes in vitro. Primary cardiomyocytes isolated from mice or rats are 
killed upon CVB infection [32, 33], and a murine cardiac muscle cell line, HL-1 [34], undergoes 
apoptosis upon CVB infection [35]. Human patients presenting with enterovirus-induced 
myocarditis who had cardiac biopsies taken showed a strong positive correlation between 
cardiomyocytes staining positive for enterovirus capsid protein and those undergoing apoptosis 
[36]. Perhaps the most convincing evidence for direct CVB-mediated cell death comes from 
mice with severe combined immunodeficiency (SCID mice). SCID mice lack all mature T- and 
B- cell responses, and therefore are incapable of developing autoimmunity. Even in a SCID 
mouse model of CVB-induced myocarditis, death of cardiomyocytes correlates with the 
development of cardiomyopathy [37]. Despite these convincing results, it remains probable that 
autoimmune responses contribute to CVB-induced myocarditis, acting in combination with cell 
death caused directly by CVB replication. In mouse models of CVB-induced myocarditis, CVB 
infection leads to the generation of heart specific autoantibodies [38], and human patients with 
viral-induced myocarditis also have autoantibodies in their sera [39]. Therefore, it is likely that 
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both CVB-induced cell death and CVB-induced autoimmunity contribute to the destruction of 
cardiomyocytes in CVB-associated cardiomyopathy. 
1.1.1.4 CVB infection of the central nervous system. As detailed in Section 1.1.1.1, CVB was 
initially isolated from patients with poliomyelitis-like symptoms. For this reason, neurological 
complications arising from CVB infections are well-studied. Both aseptic meningitis and 
meningoencephalitis, in which the brain itself is inflamed in addition to the meninges, can result 
from coxsackievirus infections [40], with neonates at particular risk [1]. An observational study 
of children admitted to a single hospital with confirmed CVB infections over an 8-year period 
noted that the most common diagnosis for these children was aseptic meningitis [41]. In a 
neonatal mouse model of CVB infection, viral protein was found exclusively in neurons and 
neuronal stem cells and the authors observed death of infected cells [42]. Additionally, neonatal 
mice infected with sublethal doses of CVB showed reduction in brain weight due to CVB-
induced apoptosis of neuronal stem cells and consequent decreased neuronal proliferation [43]. 
This animal model evidence, coupled with observations of viral antigen from group B 
coxsackieviruses in neurons and glial cells of a patient with encephalitis [44] suggests that viral 
replication in and lysis of host cells in the central nervous system (CNS) contributes to CNS 
pathology upon CVB infection, in addition to the established role for immune infiltrate in aseptic 
meningitis [45]. 
1.1.1.5 CVB infection of the pancreas. The contribution of environmental factors to the onset 
of type I diabetes in children, in which the insulin producing β-cells of the pancreatic islet are 
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destroyed, has long been suspected, and there is strong evidence suggesting that viral infections, 
and enterovirus infections in particular, can precipitate its development [24]. A meta-analysis of 
the available literature showed that patients with type I diabetes were significantly more likely to 
have evidence of an acute enterovirus infection than the general population [46], and patients 
with recent-onset type I diabetes were significantly more likely to have evidence of enteroviral 
protein in their pancreatic islets than non-diabetic controls [47]. In perhaps the most convincing 
evidence for enterovirus-induced diabetes, CVB4 was isolated from the pancreas of a young 
patient who died from diabetic ketoacidosis and this strain of CVB4 was able to cause death of 
β-cells and subsequent hyperglycemia in mice [48]. Additionally, an analysis of the pancreases 
of organ donors with type I diabetes found that 3 of the 6 pancreases had capsid protein from 
CVB4 in the β-cells of their pancreatic islets compared to 0 of 26 control pancreases [49]. There 
is also evidence that β-cell destruction upon CVB-infection may be due to molecular mimicry, in 
which a CVB protein bears molecular similarity to an autoantigen [50, 51], or by the release of a 
normally sequestered autoantigen by CVB-infection of pancreatic islets [52], both of which lead 
to an autoimmune response directed against the pancreatic islets. Clearly, group B 
coxsackievirus infections can both directly and indirectly contribute to the β-cell destruction that 
results in development of type I diabetes, though CVB4 seems to be more important in this 
pathology than CVB3. 
1.1.2 Viral Life Cycle 
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As research on the role of CVB in the pathogenesis of human disease was progressing, scientists 
understood that it was also important to understand the life cycle of CVB at a cellular level. To 
that end, much effort has been applied to understanding the mechanisms of entry, replication, 
and egress of CVB in cell culture models.  
1.1.2.1 Viral Entry. In order to enter a host cell, CVB must attach to its receptor, known as the 
coxsackievirus-adenovirus receptor (CAR) [53]. This attachment is mediated by the insertion of 
CAR into the ‘canyon’ of CVB, a depression surrounding each five-fold axis of symmetry of the 
viral capsid [54, 55]. However, as CAR is localized to the tight junction in the intestinal 
epithelium and is therefore inaccessible to CVB approaching from the intestinal lumen, it has 
been shown that CVB first binds and clusters decay-accelerating factor (DAF), a membrane-
anchored protein found at the apical surface [56]. This induces cytoskeletal rearrangements that 
allow access to CAR [56]. Once bound to CAR, CVB undergoes a conformational change 
involving rearrangement of the viral capsid proteins to become what is known as an ‘A-particle’, 
a necessary step for subsequent uncoating of the genome after internalization [57]. This altered 
particle is then endocystosed using a variety of endocytic pathways, depending on the cell type 
[56, 58-61]. The process of uncoating is not completely understood for CVB, but based on data 
from other enteroviruses, it is likely that the conformational change experienced upon A-particle 
transition results in the exposure of the terminus of the viral capsid protein VP1, expulsion of 
VP4 from the capsid, and expansion of a pore at the two-fold axis of symmetry of the viral 
capsid. The helical amphipathic tail of VP1 then inserts into the endocytic membrane, VP4 forms 
a pore in the endocytic membrane, and the expansion of the capsid at the two-fold axis of 
  9 
symmetry allows the viral genome to exit through the VP4 pore into the cytoplasm, leaving 
behind an empty capsid in the endosome [62-66]. 
1.1.2.2 Viral Replication. Once uncoating has occurred, the now cytoplasmic RNA genome 
must be both replicated and translated. The mechanisms of these processes were first thoroughly 
investigated for poliovirus, and much of the knowledge of CVB replication is extrapolated from 
these studies. As CVB does not package a polymerase within its viral capsid, translation of the 
genome must first occur in order to produce the virally-encoded polymerase. The genome of 
CVB does not contain a 5’-cap, which is used for eukaryotic translation initiation, but is instead 
covalently linked to the VPg protein at its 5’-end [67, 68]. Therefore, translation initiation occurs 
via the genomic internal ribosomal entry site (IRES) and host-cell ribosomes [69, 70]. This 
produces a polyprotein that is autoprocessed by the viral cysteine proteases 2Apro and 3Cpro 
(Figure 2) [71]. These proteases also target numerous cellular proteins for cleavage and are well 
conserved amongst enteroviruses [72-74]. The processing of 3Dpol, the viral polymerase, enables 
it to begin negative-strand synthesis from the positive-strand genome. From this negative-strand 
template, many new copies of the viral genome are synthesized [75], which are then packaged 
into capsids [76]. The process of viral replication is localized to viral replication complexes 
(VRCs) that are induced by viral proteins and require the remodeling of host subcellular 
membranes to use as platforms [77]. This process is more thoroughly introduced in section 1.7. 
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Figure 2. Polyprotein of CVB. 
The CVB genome is translated as one polyprotein that is then processed or autoprocessed into individual proteins by 
the viral protease. 
1.1.2.3 Viral Egress. Newly packaged CVB capsids must exit the cell to start a new round of 
replication in a new host cell or to exit the host. As interaction with CAR is required for the 
formation of the A-particle, and RNA cannot exit the capsid without this transition, there is no 
possibility for a newly formed virus to restart an infection in its cell of origin.  It has been long 
observed that CVB infections cause cell death in vivo and in tissue culture (see section 1.2). For 
the preponderance of its spread, CVB relies on this cell death to escape the cell. Indeed, blocking 
apoptotic cell death in HeLa cells upon CVB infection led to large reductions in release of 
extracellular virus [78]. Conversely, increasing apoptotic cell death in CVB infected HeLa cells 
through ectopic expression of the pro-apoptotic protein Cyr61 led to an increase in extracellular 
virus release, while siRNA-mediated knockdown of Cyr61 decreased extracellular virus release 
[79]. Additionally, blocking CVB-induced necrosis in intestinal epithelial cell lines through a 
variety of mechanisms all led to a decrease in extracellular virus titers [80]. The fact that diverse 
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mechanisms of cell death inhibition in different cell lines upon CVB infection all resulted in a 
reduction or delay of viral release strongly implicates cell death in the process of viral egress and 
minimizes the possibility that inhibitors of cell death were having an off target effect on a 
separate aspect of the viral life cycle. 
 Despite the strong evidence cited above for the link between viral egress and cell death, 
there is also data that suggests that there may be secondary routes of viral egress that occur 
temporally before and independently of cell death. One such route may involve autophagy, 
which is thoroughly introduced in section 1.7. Neural progenitor cells infected with CVB shed 
extracellular microvesicles derived from autophagic pathways containing infectious CVB virions 
before any signs of cell death [81], and HeLa cells shed CVB in phosphatidylserine lipid-
enriched vesicles before lysis [82]. Additionally, pharmacologically blocking the autophagy 
pathway in CVB-infected HeLa cells resulted in a reduction of extracellular virus, though this 
data is difficult to interpret in the context of autophagy as an egress pathway as treatment also 
reduced intracellular virus replication [83]. 
1.2 CVB INFECTION AND CELL DEATH 
It is quite clear from the discussion of CVB pathogenesis in section 1.1.1 that cell death caused 
by CVB infection has serious consequences for human health. Cell death upon viral infection 
causes pathologies in the heart, CNS, and pancreas. Much research has been done concerning the 
mechanisms by which cell death occurs upon CVB infection.  
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Cells possess diverse routes of cell death initiation, from cell surface receptors such as 
the tumor necrosis factor receptor 1 (TNFR1) [84], to intracellular receptors known as pattern 
recognition receptors (PRRs) that sense pathogen or damage associated molecular patterns 
(PAMPs or DAMPs, respectively) [85], to the detection of DNA damage. Additionally, distinct 
forms of cell death can occur downstream of these triggers. Apoptosis, in either its caspase-
dependent or caspase-independent form, is a tightly regulated form of cell death that results in 
chromatin condensation, DNA fragmentation, and the eventual disruption of the cell into 
apoptotic blebs [86]. Caspases are proteases that require proteolytic processing for activation, 
and, once activated, cleave downstream substrates to induce apoptotic cell death [87, 88]. 
Apoptosis is further categorized as intrinsic or extrinsic. Intrinsic apoptosis is mediated by the 
mitochondria and is dependent on the release of cytochrome C from the mitochondria, a process 
that is regulated by the Bcl-2 family of proteins. Pro-apoptotic Bcl-2 family members act to 
release cytochrome C from the mitochondria whereas anti-apoptotic family members act to 
prevent cytochrome C release. Extrinsic apoptosis, on the other hand, proceeds from cell surface 
receptors and is independent of the mitochondria [89]. Necrosis was long thought to be an 
unregulated form of cell death, characterized by loss of membrane integrity and a release of 
intracellular contents into the extracellular space that provoked a highly inflammatory reaction. 
Recently, programmed forms of necrosis have been discovered, with tightly regulated signaling 
cascades that result in membrane permeabilization by the mixed lineage kinase like protein 
(MLKL) and/or generation of reactive oxygen species (ROS) and lead to the necrotic death 
phenotype [90] (discussed thoroughly in section 1.5). [91]. In vitro studies of CVB infections in 
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cell culture models reveal that multiple redundant pathways are likely triggered to initiate cell 
death upon infection and the cell death pathways induced are cell type specific. 
1.2.1 CVB-Induced Apoptosis 
There is much evidence to suggest that apoptosis is a relevant in vivo form of cell death induced 
by CVB. Infected cardiomyocytes from patients with enterovirus-induced myocarditis were 
apoptotic [36], and primary rat pancreatic cell cultures died by apoptosis upon CVB5 infection 
[92]. Further in vitro work shows that infection with various CVB serotypes in HeLa cells leads 
to cytochrome C release from the mitochondria [78], a hallmark of intrinsic apoptosis. This 
release is followed by caspase-activation [93], specifically caspase 9 [78, 94], an initiator caspase 
that cleaves other caspases. Indeed, CVB infection results in activation of caspases-2, -3, -6, -7, -
8, and -9 in HeLa cells [78, 93].   
Although these studies clearly show that CVB induces apoptotic cell death in specific cell 
types both in vivo and in vitro, it remains to be explained how this apoptosis is mechanistically 
induced during viral infection. One such apoptosis-inducing mechanism is the activation of the 
unfolded protein response (UPR). The UPR, under normal cellular circumstances, is a cell-wide 
response to the accumulation of unfolded proteins in the endoplasmic reticulum (ER) [95], and 
can trigger apoptotic cell death [96]. CVB infection in HeLa cells induced the UPR through each 
of the three distinct UPR initiation pathways (the PERK, IRE1, and ATF6 dependent pathways) 
[97], and resulted in activation of caspase-12, a UPR specific caspase [98], and upregulated 
expression of CHOP, a pro-apoptotic transcription factor classically implicated in UPR-initiated 
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cell death [97, 99]. Alternatively, CVB infection can trigger apoptosis through the activation of 
stress activated protein kinases (SAPKs). SAPKs, including JNK and p38MAPK, are responsible 
for sensing cell stressors and transducing the signal to induce cellular responses to those 
stressors, including induction of cell death pathways [100, 101]. p38MAPK was phosphorylated 
and activated upon CVB infection of HeLa cells or a murine cardiomyocyte cell line [102, 103], 
and pharmacological inhibition of p38MAPK reduced CVB-induced cell death [102].  
 There is also much data available on the subject of the mechanisms by which CVB 
infection initiates the above cell death pathways. Transient overexpression of the CVB-encoded 
cysteine proteases 2Apro or 3Cpro in HeLa cells is sufficient to reduce cell viability, activate 
caspases, and induce cytochrome C release from the mitochondria [104]. The mechanism of 
death induction by these proteases is dependent on proteolytic activity, as a catalytically inactive 
mutant of 3Cpro cloned from a closely related enterovirus, EV71, was incapable of inducing the 
apoptotic cell death induced by the wild-type protease in a glioblastoma cell line [105]. Cleavage 
of host cell proteins by these proteases likely feeds into the apoptotic pathways discussed above 
in multiple ways. A second mechanism by which apoptosis is triggered during CVB infections 
may be through production of double-stranded (ds)RNA during the course of genome 
replication. dsRNA is a highly immunogenic PAMP that can also lead to the induction of cell 
death [85, 106]. Multiple intracellular sensors of dsRNA exist and serve to activate innate 
immune signaling and can cross-talk with cell death pathways. Melanoma differentiation 
associated 5 (MDA5), a cytosolic dsRNA sensor, and toll-like receptor 3 (TLR3), an endosomal 
dsRNA sensor are both key sensors of CVB infection [107] (see section 1.3), and CVB infection 
induces expression of another cytosolic dsRNA sensor, protein kinase R (PKR) [108]. Finally, 
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viral capsid proteins themselves may serve to initiate apoptosis. CVB-encoded VP2, one of four 
viral proteins that compose CVB capsids [72], physically interacts with the pro-apoptotic host 
protein Siva [109, 110]. Siva functions by binding to Bcl-XL, an anti-apoptotic member of the 
Bcl-2 family and sequestering it, thus preventing it from carrying out its anti-apoptotic function 
[111]. Infection of a mouse model with CVB containing a mutation in VP2 preventing SIVA 
binding showed lower levels of cell death in the pancreas than wild-type CVB, despite similar 
viral titers [109]. The mechanism(s) by which VP2 binding to SIVA enhances its apoptotic 
function is not fully understood.  
1.2.2 CVB-Induced Necrosis 
In contrast to the large amount of data available on apoptotic cell death during CVB infection, 
much less is known about the contribution of necrotic cell death. One reason for this dearth of 
data is the only recent development of the programmed necrosis (’necroptosis’) field. Another is 
that in many of the cell types studied in vitro, the main cell death pathway induced upon CVB 
infection is apoptosis and necrosis seems to be uninvolved, or not involved to any significant 
degree (as discussed in section 1.2.1). However, our group has recently shown that a polarized 
intestinal epithelial cell (IEC) line undergoes calpain-mediated necrotic cell death upon CVB 
infection, dependent upon Ca2+ release from the ER [80]. Another study showed that a pancreatic 
islet cell line that undergoes apoptosis when infected with CVB5 at a low multiplicity of 
infection (MOI), may instead undergo necrosis at higher MOIs. However, the method used here 
to characterize and quantify necrosis was not robust [112]. It is likely that both necrosis and 
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apoptosis are relevant forms of cell death in vivo, as EV infections must cross the polarized IEC 
barrier to cause initial viremia, and intestinal epithelial cells die necrotically in vitro (above, 
[80]) whereas apoptotic cell death seems most relevant at the distal sites of infection resulting in 
pathology (myocardium, pancreatic islets, and the CNS).  
1.3 CVB INFECTION AND INNATE IMMUNE SIGNALING 
In addition to being the cause of a number of pathologies associated with CVB infection and 
necessary for CVB egress, cell death can also be an important part of the innate immune 
response to an intracellular pathogen. It has long been appreciated that the intracellular innate 
immune response, comprised of a variety of signaling pathways designed to alert a host cell and 
its neighboring cells to a pathogenic invader, is necessary for the induction of the subsequent 
adaptive immune response [113, 114]. Innate immunity to pathogens is largely mediated by 
PRRs, which recognize a variety of PAMPs that are highly conserved amongst classes of 
pathogens [115]. During a viral infection, PRRs induce an intracellular signaling cascade in 
response to recognition of their cognate PAMP that results in the alteration of the transcription 
profile of the host cell or may lead to cell death.  Two major classes of transcription factors are 
activated in response to this signaling: Interferon Regulatory Factors (IRFs) and nuclear factor 
kappa-light-chain-enhancer of B cells (NF-κB) family members. These transcription factors act 
in concert to induce the expression of type I interferon (IFN) [116]. These auto- and paracrine 
signaling molecules serve to upregulate a cadre of genes, known as interferon stimulated genes  
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(ISGs).  The effects of type I IFNs and ISGs are legion; they are pro-inflammatory [117], 
enhance adaptive immunity [118], and are directly antiviral [119].  Additionally, NF-κB 
activation induces a host of pro-inflammatory and pro-survival genes independently of type I 
IFN induction [120-123] and may be required for full induction of type I IFNs [121, 124]. The 
two classes of PRRs known to be most critical in sensing CVB infection (detailed below) are the 
TLRs and the RIG-I like receptors (RLRs).  
TLRs 1-13 are transmembrane PRRs that recognize a diverse range of PAMPs.  TLRs 
can be divided into two broad categories—those that are localized to the cell surface and those 
that are localized to the endosomal lumen. TLRs that are present on the cell surface are important 
in recognition of bacterial pathogens. In contrast, TLRs that are localized to the lumen of 
endosomes, TLRs 3, 7, 8, and 9, serve to recognize nucleic acids and are thus traditionally 
thought to be the most important in the promotion of an antiviral response. TLR3 recognizes 
dsRNA and the synthetic dsRNA structural homolog poly(I:C) [106]. TLR7 and TLR8 recognize 
ssRNA and imidazoquinoline compounds [125-128]. TLR9 recognizes unmethylated 
deoxycytidylate-phosphate-deoxyguanylate (CpG) DNA, found almost exclusively in bacteria 
[129, 130]. 
RLRs are a group of cytoplasmic PRRs comprised of three members: retinoic acid-
inducible gene (RIG)-I, MDA5, and laboratory of genetics and physiology (LGP)2. RIG-I 
recognizes cytoplasmic short dsRNA and 5’ppp-ssRNA [131-134]. MDA5 binds the internal 
duplex structure of cytoplasmic long dsRNA and cooperatively assembles into a filamentous 
oligomer composed of MDA5 dimers [132, 135-140].  The role of LGP2 has not been 
thoroughly elucidated.  Early studies suggested that it acted as a negative regulator of RIG-I and 
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MDA5 [141-143]. However, further studies revealed that LGP2 was essential for type I IFN 
response to picornavirus infections in mice and that LGP2 with active helicase activity is 
required for IFNβ production in response to various RNA viruses in dendritic cells (DCs) and 
mouse embryonic fibroblasts (MEFs) [144]. Further studies of LGP2 have yielded equally 
disparate results, as both overexpression of chicken LGP2 and knockdown of endogenous LGP2 
in chicken cells resulted in reduced IFNβ production in response to avian influenza infection 
[145]. 
1.3.1 TLR-mediated CVB sensing 
TLR3 has been shown to play an essential and non-redundant role in the response to CVB, and 
may be the most critical TLR in the control of CVB infection. TLR3-deficient mice exhibit 
significantly increased mortality in response to a dose of CVB4 that is sublethal in control mice 
[146]. TLR3 also plays a protective role in restricting CVB infection in the heart as TLR3-/- mice 
infected with CVB display increased mortality and myocarditis [147]. TRIF-/- mice infected with 
CVB display increased viral replication in myocytes, decreased left ventricular functioning, and 
increased cardiac fibrosis [148]. Further supporting a role for TLR3 in CVB-triggered innate 
immune signaling, human patients diagnosed with enterovirus-induced myocarditis have 
increased frequencies of two single-nucleotide polymorphisms (SNPs) in TLR3 which result in 
variants that exhibit a reduced capacity to promote type I IFN and NF-κB signaling in vitro in 
response to poly(I:C) or CVB infection [149]. This suggests that sensing CVB-infection by 
TLR3 is key to activation of an effective immune response that can eliminate infection. 
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In addition to TLR3, several other TLRs have been shown to be important in the sensing 
of CVB infections. TLR4, which is localized to the cell surface, has also been shown to be 
important in the detection of CVB, although it is mainly studied in the context of bacterial 
pathogens. It has been shown that TLR4 mediates the production of  tumor necrosis factor 
(TNF)α and interleukin (IL)-6 in pancreatic cells infected with CVB4, suggesting a role for 
TLR4 in recognizing not only bacterial lipopolysaccharides (LPS), but viral proteins as well 
[150], and implicating TLR4 in the production of pro-inflammatory cytokines that may 
contribute to pancreatic damage in CVB-precipitated type I diabetes. Additionally, the level of 
TLR4 expression and the level of enteroviral RNA present in endomyocardial tissue of patients 
with myocarditis are positively correlated [151]. However, in contrast to the studies described 
above related to TLR3 signaling, much less is known regarding the consequences of TLR4 
signaling on CVB infection in vivo.  
The ssRNA sensors TLR7 and TLR8 have also been shown to play some role in the 
induction of antiviral signaling in response to CVB infection, although their precise function 
remains largely unclear [152-154]. TLR7 has been shown to be required in plasmacytoid 
dendritic cells (pDCs), also known as interferon-producing cells because of their role in 
producing copious amounts of type I IFNs [155], for the production of IFNα and IL-12p40 in 
response to CVB, although this role was dependent on CVB specific antibody-mediated 
opsonization of the virus [154]. It has been shown that knockdown of endogenous TLR8 in 
primary human cardiac cells critically abrogates the capacity of those cells to produce IL-6 in 
response to CVB infection [153]. This suggests that the damaging cardiac inflammation seen in 
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CVB-induced myocarditis may be mediated through sensing of viral RNA by TLR8. However, 
little is known regarding the role of these TLRs in the control of CVB infections in vivo.  
1.3.2 RLR-mediated CVB sensing 
As the CVB genome is covalently linked to the VPg protein, it does not have a 5’-ppp motif that 
would be expected to be sensed by RIG-I.  Indeed, MDA5, but not RIG-I serves as a cytoplasmic 
sensor for CVB. In vitro, MDA5-/- MEFs but not RIG-/- MEFS were unable to produce type I IFN 
in response to transfection of CVB genomic RNA [156]. MDA5 mediated responses to CVB 
RNA have been shown to be largely dependent on direct interaction of MDA5 with the dsRNA 
replicative intermediate form [139, 156]. The role of MDA5 also seems relevant in vivo, as in 
one study both MAVS and MDA5 deficient mice showed increased mortality and decreased 
systemic and tissue specific type I IFN upon CVB infection [157]. While a second study 
confirmed that MDA5 deficient mice were indeed more susceptible to CVB infection, as 
demonstrated by increased mortality, this study found that MDA5 seemed to be dispensable for 
production of systemic IFNα and tissue specific IFNβ in CVB3-infected mice [158]. These 
disparate results may be due to differences in the MDA5-/- mice used in the studies; the two 
studies used MDA5-/- mice generated on disparate genetic backgrounds [157] [158].   
A link between the development of fulminant type I diabetes, a subset of type 1 diabetes 
characterized by rapid onset [159], and the sensing of CVB infection via RLRs has also been 
suggested. Both α- and β-cells in the pancreas of fulminant type I diabetics with enterovirus 
infection showed hyperexpression of RIG-I and MDA5 whereas non-fulminant diabetics without 
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enterovirus infections did not show this association [160]. However, the molecular basis for 
these results requires further study. 
1.4 VIRUS-HOST CELL INTERACTIONS DURING CVB INFECTION 
Section 1.1.2.2 introduced the extensive remodeling of the host cell effected by viral proteins in 
order to set up viral replication complexes. Here, the ways in which viral proteins, particularly 
viral proteases, alter host cell translation, cell death signaling, and innate immune signaling are 
thoroughly examined. These interactions are summarized in Table 1. 
 
CVB Protein Role in Interacting with Host Cell 3Cpro Cleaves TRIF 3Cpro Cleaves MAVS 3Cpro Cleaves FAK 2Apro Cleaves PABP 2Apro Cleaves eIF4-G 2B Inserts into ER membrane 
Table 1. Virus-Host Cell Interactions 
1.4.1 CVB and host cell translation 
There is a significant body of work detailing the ability of the CVB proteases 2Apro or 3Cpro to 
cleave a number of factors involved in host-cell transcription and translation. As CVB utilizes its 
own encoded polymerase to copy its genome and an IRES to initiate translation (section 1.1.2), 
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this allows the virus to disable host cell protein production while continuing to produce its own 
proteins [161]. Several host cell proteins required for the initiation of mRNA translation are 
cleaved directly by 2Apro, including eukaryotic initiation factor 4G (eIF4-G) [162, 163] and 
poly(A)-binding protein (PABP) [164]. In the case of poliovirus infection, proteins involved in 
the transcription of host cell genes are also targeted by viral proteases for cleavage, such as 
transcription factor IIIC (TFIIIC) [165], and the TATA-binding protein (TBP) [166]; it has not 
been interrogated whether TFIIIC and TBP are also targeted for cleavage during CVB infection, 
though the high degree of conservation among enteroviruses of the sequence identity and 
function of the virally-encoded proteases suggests that this is likely.  
1.4.2 CVB and cell death signaling 
Cell death can serve as a mechanism to eliminate intracellular pathogens before they complete 
their replication cycle. CVB possesses several mechanisms of delaying cell death, in order to 
counter the fact that CVB infection potently induces cell death pathways, as discussed in section 
1.2. One such mechanism is through the manipulation the phosphatidylinositol 3-kinase (PI3K) 
signaling pathway, a pro-survival pathway activated by many viruses to delay or inhibit cell 
death [167]. CVB infection of HeLa cells leads to activation of PI3K and subsequent 
phosphorylation of downstream effector kinase, Akt (also known as protein kinase B). Inhibition 
of this pathway led to more apoptosis and decreased CVB release [168]. These data may be 
complicated by the additional role PI3K plays in regulating autophagy [169, 170], as effects on 
CVB release upon PI3K inhibition may additionally be due to inhibition of autophagy (section 
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1.7). One group showed that the PI3K/Akt pathways could be activated in CVB-infected HeLa 
cells through the action of interferon-γ-inducible GTPase (IGTP) [171], a protein upregulated in 
CVB-infected murine myocardial tissue [172]. Activating transcription factor 3 (ATF3) has been 
shown to sensitize HeLa cells to CVB-induced apoptosis, but CVB infection leads to an abrupt 
and significant reduction in ATF3 protein levels that serves to reduce cell death [173].  
CVB-encoded proteases 2Apro and 3Cpro can also directly target host proteins involved in 
cell death signaling for proteolytic cleavage and inactivation. For example, 3Cpro cleaves Toll/IL-
1 receptor domain containing adaptor inducing interferon-beta (TRIF), a protein involved in 
apoptotic signaling, and inhibits its apoptotic functions [174]. Another example of a viral protein 
directly inhibiting cell death is the viral protein 2B. Expression of the CVB nonstructural protein 
2B causes Ca2+ release through its ability to from pores in the ER membrane [175]. Because Ca2+ 
efflux from the ER and its subsequent influx into the mitochondria is known to cause apoptosis 
[176], it may seem that 2B would then be a pro-apoptotic protein. And indeed, in some cases 
viral proteins causing release of Ca2+ stores are pro-apoptotic [177]. However, 2B of CVB seems 
to prevent apoptosis through destruction of the Ca2+ gradients necessary for the cell to initiate 
intrinsic apoptosis [178, 179].  
1.4.3 CVB and innate immune signaling 
CVB targets both TLR and RLR signaling pathways for proteolytic cleavage upon infection. The 
CVB protease 3Cpro cleaves the TLR3 adaptor TRIF upon infection, as discussed in section 1.4.2, 
and the resultant TRIF fragments were non-functional [174]. MAVS is also targeted for cleavage 
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by 3Cpro and the cleavage fragments were functionally deficient in NF-κB and type I IFN 
signaling when compared to full-length MAVS, resulting in attenuation of IFNβ-signaling [174]. 
Finally, 3Cpro also targets the RLR signaling pathway through direct cleavage of focal adhesion 
kinase (FAK), which is recruited to mitochondria upon viral infection and potentiates MAVS 
signaling by an as-yet-undefined mechanism [180].  
1.5 UNC93B AND TOLL-LIKE RECEPTOR TRAFFICKING  
As introduced in section 1.3, TLRs are important PRRs involved in sensing both viral and 
bacterial infections. Tight regulation of TLR signaling is important, as aberrant TLR signaling, 
especially recognition of self-antigens, leads to a variety of disease states [181], including 
systemic lupus erythematosus (SLE) [182]. One key mechanism of regulation of TLR signaling 
is through the regulation of the subcellular localization of TLRs, as correct localization of TLRs 
can preclude the possibility of recognition of a self-antigen [183, 184]. Therefore, much work 
has been done to elucidate the mechanism of trafficking of TLRs. Here, the focus remains on 
trafficking of endosomal TLRs, those TLRs most relevant to the recognition of CVB infection 
(see section 1.3.1).  
Upon initial synthesis, TLRs 3, 7, and 9 are inserted into the endoplasmic reticulum as 
transmembrane, full-length proteins [185-187]. In order for these TLRs to be functional, they 
must be both translocated to the endosome and proteolytically processed. This processing is 
carried out by acid-dependent proteases in the endolysosomal compartment [187-191]. Unlike 
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TLRs 7 and 9, which are primarily found in the ER in resting cells [185, 186], a significant pool 
of processed TLR3 is found in the endosome, ready to signal, in resting cells [187]. The 
mechanism for this differential regulation is not well understood.  
The trafficking of these TLRs from the ER to the endosome, as well as the trafficking of 
TLR5 to the cell surface, is carried out by Unc93b, an ER-resident transmembrane protein [186, 
192-195]. Unc93b serves as a chaperone, binding its client TLRs in the ER and trafficking them 
to their appropriate subcellular locations where they are then available to sense their cognate 
ligands [186, 196].   
 The function of Unc93b was initially discovered through a forward genetic screen in 
mice in which mice expressing a non-functional point mutant of Unc93b, (H412R), were shown 
to be sensitive to a diverse group of pathogens [192]. Unc93bH412R is incapable of binding its 
client TLRs [196] or exiting the ER [186, 197], resulting in cells that are not sensitive to 
endosomal TLR ligands.  
 The trafficking of TLR9 by Unc93b has been best studied. While it is likely that Unc93b 
traffics its other client TLRs using a similar mechanism, there is data to show that Unc93b is 
capable of discriminating between endosomal TLRs for trafficking purposes. For example, 
mutation of a single amino acid in the N-terminus of Unc93b favors trafficking of TLR7 over 
TLR9, suggesting selective trafficking by Unc93b [198, 199]. In the case of TLRs 3, 7, or 9, 
Unc93b binds its client TLR in the ER and mediates its transit from the ER to the Golgi 
compartment in coat protein II (COPII) vesicles [197]. From the Golgi, Unc93b-TLR9 
complexes travel to the cell surface through an unspecified mechanism where a C-terminal Yxxϕ 
motif in Unc93b is necessary to recruit AP2, which serves to trigger endocytosis of the Unc93b-
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TLR9 complex and results in endosomal TLR9 localization [197, 200]. Surprisingly, this AP2 
recruitment was not necessary for TLR7 trafficking. Instead TLR7 itself seems to recruit AP4 
directly while it is in the Golgi and uses this to traffic directly to the endosomal compartment 
[197]. TLR3 trafficking past the Golgi is not yet understood in any detail.  
 Unc93b function is important for the control of several important pathogens, including 
CVB. Mice expressing a non-functional Unc93b mutant were much more susceptible to CVB-
induced myocarditis, for example [201]. By controlling the subcellular localization of endosomal 
TLRs, Unc93b sits at an important nexus of innate immune control, balancing the promotion of 
pathogen recognition with the prevention of self-antigen recognition. 
1.6 RIP3-DEPENDENT NECROPTOSIS 
A living cell may become a non-living cell in one of two ways—(1) the cell may be subject to 
such extreme mechanical or chemical forces that its internal architecture collapses in a 
completely non-regulated process, or (2) the cell may, through sensing of some component of its 
environment, initiate cell death utilizing genetically encoded pathways whose purpose is to end 
the life of the cell. The first type of cell death is considered ‘accidental cell death’, in contrast to 
the second type of cell death, known as ‘programmed cell death’ [202]. The concept of 
programmed cell death was tangentially introduced in section 1.2. Here, the focus is directly on 
the idea of programmed cell death, specifically necrotic programmed cell death. Death by 
apoptosis is the classical form of programmed cell death, which occurs by well-characterized, 
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tightly controlled signaling pathways [86, 203]. In contrast, necrosis was long considered to be a 
form of accidental cell death, with cell swelling leading to membrane rupture and an 
inflammatory spillage of cellular contents. However, in the past 15 years, evidence began to 
emerge that necrosis may be programmed, with genetically encoded pathways serving to execute 
necrotic death functions [204, 205]. Investigation into this hypothesis led to the discovery of 
receptor interacting protein kinase 3 (RIP3), the central kinase in programmed necrotic cell 
death, now referred to as necroptosis [202, 206-209]. Here, the role of RIP3 in necroptosis is 
introduced.   
1.6.1 Cellular mechanisms of necroptosis 
1.6.1.1 Activation of necroptosis. Necroptosis is defined as a RIP3-dependent form of regulated 
necrosis, which is sometimes also dependent on fellow receptor interacting protein kinase family 
member, RIP1 [202, 209]. Activation of necroptosis depends on phosphorylation of RIP3 and 
assembly of RIP3 into a signaling complex with either RIP1 or other partners. Here, the various 
mechanisms by which this process is known to be initiated are discussed. 
 Necroptosis was originally observed as a consequence of ligation of death receptor family 
members such as TNFR1 [205-208]. Though it is now understood that a variety of upstream 
triggers can lead to necroptosis, necroptotic signaling is still best characterized in the context of 
death receptor ligation. The ligation of TNFR1 by TNFα can result in three distinct outcomes for 
the cell. First, ligation of TNFR1 can lead to pro-survival, pro-inflammatory NF-κB signaling. 
Second, it can lead to apoptosis. Third, it can lead to necroptosis. This diversity of outcomes is 
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achieved by a series of signaling complexes whose assembly is dependent on cellular context. 
Upon ligation, TNFR1, a transmembrane cell surface receptor, recruits what is known as 
Complex-I, the core of which consists of the proteins TRADD (tumor necrosis factor receptor 
type 1-associated DEATH domain protein) [210], RIP1 [211], and TRAF2 (tumor necrosis factor 
receptor associated factor 2) [212, 213]. In Complex-I, RIP1 is in a ubiquitinated state [214] and 
this serves to initiate NF-κB signaling [215, 216]. The ubiquitination of RIP1 is carried out by 
cIAPs (cellular inhibitor of apoptosis proteins) [217-219]. The deubiquitination of RIP1 [220], 
which is carried out by the deubiquitinase CYLD (cylindromatosis) [221, 222], favors the 
disassembly of Complex-I and the assembly of Complex-II, which serves to initiate apoptotic 
signaling. This entails the dissociation of Complex-I from TNFR and the subsequent recruitment 
of FADD (Fas-associated protein with death domain) and caspase 8 to Complex-I [215]. Finally, 
inhibition of apoptosis through caspase inhibition leads to recruitment of RIP3 to Complex-II, 
which is now known as the necrosome or Complex-IIb, and the initiation of necroptosis [206-
208]. 
 Subsequent work showed that a necroptotic signaling complex can form in the absence of 
TNFR1 signaling. This spontaneously assembling complex, termed the ripoptosome, consists of 
RIP1, FADD, and caspase 8, much like Complex II. However, this complex forms in the absence 
of TNF signaling and instead requires depletion of cIAPs, which occurs during genotoxic stress, 
among other conditions. RIP3 can be recruited into this complex and this results in the initiation 
of necroptosis [223, 224]. 
 Necroptosis has also been shown to occur downstream of a variety of pattern recognition 
receptors, with the term ripoptosome or necrosome also being applied to the necroptotic 
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signaling complex assembling downstream of these PRRs. TLR3 and TLR4 both utilize the 
adaptor protein TRIF to transduce their signals. TRIF can recruit RIP3 in a RIP1-independent 
manner, and this TRIF-RIP3 complex can induce necroptotic signaling [225, 226]. The 
cytoplasmic DNA sensor DAI is also capable of recruiting RIP3 in a RIP1-indepenent manner, 
resulting in necroptosis [227]. There is also some evidence showing that T cell receptor ligation 
on T cells may lead to necroptosis, though this is not as yet a well-developed area of research 
[228, 229]. 
 Both type I IFN and type II IFN signaling can lead to necroptosis. Type I or II IFN 
signaling in MEFs and Type II IFN signaling in murine macrophages resulted in formation of the 
RIP1-RIP3 necrosome and subsequent necroptosis, though in MEFs necroptosis required 
destabilization of the FADD-RIP1 complex or caspase inhibition. Surprisingly, activation of the 
necrosome relied on phosphorylation of RIP1 by PKR [230]. A separate study also showed that 
type I IFN signaling resulted in necroptosis in murine macrophages, but in contrast to the 
previous study, this necroptosis was independent of PKR [231]. The mechanisms for IFN 
induced necroptosis remain to be clarified. 
 Finally, an interesting new study has shown that ER stress results in necroptosis 
dependent on both RIP1 and RIP3, though the mechanism for this induction is not clear [232]. 
 Taken together, these data support a model by which a variety of stimuli converge on a 
single RIP3-dependent pathway to induce necroptosis. 
1.6.1.2 Negative regulation of necroptosis. A number of studies in mouse models have shown 
that loss of proteins involved in extrinsic apoptosis leads to uncontrolled RIP3-dependent 
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necroptosis in vivo. This suggests that constitutive negative regulation of necroptosis is necessary 
for prevention of aberrant cell death. 
The best characterized negative regulator of necroptosis is caspase 8 [233]. As detailed 
above, caspase 8 is recruited to Complex-II upon TNFR ligation, and is involved in the execution 
of apoptosis through cleavage of downstream effector caspases 3 and 7 [234, 235]. Recently it 
has been found that caspase 8 also cleaves RIP1 [218], RIP3 [236], and CYLD [237] to 
negatively regulate necroptosis [233]. Caspase 8 is itself regulated by cFLIP (cellular FLICE-
inhibitory protein), which exists in two isoforms, cFLIPS and cFLIPL [238]. Both cFLIPS and 
cFLIPL inhibit caspase-8 mediated initiation of apoptosis through formation of a heterodimer 
with caspase 8, preventing the caspase 8 homodimerization that is necessary for autoprocessing 
and apoptosis activation [238]. The cFLIPS-caspase 8 heterodimer is also incapable of disabling 
the necroptotic pathway. However, the cFLIPL-caspase 8 heterodimer is still competent to 
proteolyze local substrates, such as RIP1, RIP3 and CYLD, an event that does not require 
autoprocessing of caspase 8 [233, 239, 240]. Together, these data suggest a complex situation of 
regulation in which caspase 8, through its proteolytic activity, negatively regulates necroptosis, 
and the presence of cFLIP isoforms regulates the proteolytic activity of caspase 8. 
The importance of caspase 8 in restricting necroptosis is underlined in evidence from 
mouse models lacking caspase 8 or its fellow Complex-II proteins, FADD and cFLIP. Caspase 8-
/- mice are not viable and experience massive necrotic cell death during embryogenesis, but 
caspase-8-/-/RIP3-/- mice are viable [241]. Similarly, mice lacking FADD in their intestinal 
epithelial cells (FADDIEC-KO) exhibit spontaneous pathologies in the colon due to necrotic cell 
death of the epithelium, but FADDIEC-KO/RIP3-/- mice do not exhibit such pathologies [242]. This 
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does not seem to be a cell-type specific phenomenon, as mice lacking FADD in their epidermal 
keratinocytes exhibit similar RIP3-dependent necroptotic phenotypes in those cells [243]. 
IAP family members cIAP1, cIAP2, and XIAP (X-linked IAP) also negatively regulate 
necroptosis [223, 224, 244]. While these proteins are known to ubiquitinate RIP1, recent 
evidence has shown that they may also ubiquitinate RIP3 in order to repress necroptosis [245]. 
Surprisingly, recent evidence has emerged that RIP1 negatively regulates necroptosis 
under certain circumstances, though RIP1 is required for and positively regulates TNFα-
mediated necroptosis, as discussed above. RIP1-/- mice die soon after parturition, as do RIP1-/-
/caspase 8-/- and RIP1-/-/RIP3-/- mice, but it was observed that RIP1-/-/RIP3-/-/caspase 8-/- mice are 
viable [246-248]. This observation led to further characterization of the role of RIP1, and it was 
found that while RIP1 kinase activity is indeed required for TNFα-mediated necroptosis, RIP1 
has an alternate, kinase-independent function of inhibiting TRIF-mediated, IFN-mediated, and 
spontaneous necroptosis [246, 247, 249].  
Recently, Ppm1b, a phosphatase that dephosphorylates RIP3 to negatively regulate 
necroptosis, was discovered [250]. Loss of Ppm1b led to spontaneous necroptosis [250], and 
Ppm1b-/- mice are not viable [251] indicating that Ppm1b regulates RIP3 under resting 
conditions. 
1.6.1.3 Necroptosis signaling. The diversity of RIP3-containing complexes detailed above 
necessitates an explanation of how such diverse complexes are all capable of initiating 
necroptosis. One key to activation of necroptosis is the structure of the RIP3 complexes formed. 
RIP3 contains a RIP homotypic interaction motif (RHIM) domain, a protein-protein interaction 
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motif capable of associating with other RHIM domains [252]. RIP1, TRIF, and DAI, all of which 
are capable of complexing with RIP3 to induce necroptosis, all also contain RHIM domains 
[252-255]. RIP1 and RIP3 form RHIM domain dependent amyloid filamentous complexes 
containing many RIP1-RIP3 heterodimers [256]. RIP3 in these amyloid fibrils further recruits 
free RIP3 molecules and autophosphorylation of RIP3 then serves to potentiate signaling [257]. 
 Once RIP3 is activated by phosphorylation of Ser-227 [258] within necrosomes [256], it 
physically associates with the pseudokinase mixed lineage kinase domain-like protein (MLKL) 
[259]. RIP3 then phosphorylates MLKL at Thr-357 and Ser-358 [258]. The interaction between 
RIP3 and MLKL is necessary for the prevention of accumulation of non-functional RIP3 
aggregates as well as translocation of the necrosome to the mitochondria-associated membrane 
(MAM), from whence it potentiates its signaling [260]. The formation of this RIP3-MLKL 
complex is key to downstream events, as blocking its formation inhibits necroptosis [258]. 
1.6.1.4 Necroptosis effector mechanisms. It was initially thought that cell death upon 
necroptosis was mediated by the generation of reactive oxygen species (ROS) with activation of 
MLKL being a secondary mechanism. However, data showing that MLKL-/- mice were 
completely resistant to TNFα-induced necroptosis established MLKL activation as the key 
effector mechanism of necroptosis [261, 262]. Later data showed that ROS production was not 
necessary for necroptosis but often accompanies it [263]. Instead, death is effected during 
necroptosis by clustering of activated MLKL into tetramers or trimers which then translocate to 
lipid rafts of the plasma membrane through a domain that interacts with phosphatidyl inositol 
phosphates [264-266]. Phosphorylation of MLKL serves to effect a structural rearrangement of 
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MLKL, allowing the formation of a pore through which uncontrolled ion efflux can lead to 
plasma membrane rupture [267, 268]. There is also some evidence that MLKL oligomers may 
interact with the Ca2+ channel protein transient receptor potential cation channel, subfamily M, 
member 7 (TRPM7) to lead to Ca2+ influx [265]. The importance of MLKL-mediated necroptosis 
was confirmed in vivo; animal models have suggested that necroptosis is a key pathway in drug-
induced liver injury [269], and liver biopsies of human patients suffering from drug-induced liver 
injury showed significant increases in phosphorylated MLKL by immunohistochemistry [270]. 
The best-characterized mechanisms of RIP3-dependent necroptosis are summarized in Figure 3.  
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Figure 3. Cellular Mechanisms of Necroptosis 
RIP3 mediates necroptosis downstream of diverse stimuli, including ligation of TNFR, TLR3, TLR4, and DAI. This 
results in phosphorylation of MLKL and translocation of trimerized or tetramerized MLKL to the plasma membrane 
where it forms a pore, facilitates ion dysregulation, and leads to compromise of the plasma membrane. The yellow-
circled P represents a phosphate group. 
1.6.2 Necroptosis and microbial infections 
Cell death pathways are a key part of host defense against pathogens, and, accordingly, 
necroptosis has been shown to play an important role in many microbial infections. However, 
work in this field has been complicated by the discovery of an alternative RIP1-RIP3 pathway, 
which leads not to necroptosis but instead to inflammasome activation. This pathway is activated 
by various stimuli, including RNA virus infection, and is effected by the RIP1 substrate DRP1 
(dynamin related protein 1) through a mechanism involving mitochondrial damage and ROS 
generation [271]. This could explain early data suggesting that necroptosis was effected by ROS 
generation; it is possible this alternative pathway was being activated concurrently with 
necroptosis in those cases.  
Despite this complication, it is clear that necroptosis itself is also important in the control 
of several pathogen infections. The best developed line of evidence for this has to do with 
murine cytomegalovirus infections (mCMV). mCMV encodes a structural protein, known as 
M45 or vIRA (viral inhibitor of RIP activation), that contains a RHIM domain and can interact 
with with RIP1 and RIP3 [272]. Upon infection, mCMV triggers a necroptotic pathway that is 
dependent on DAI and RIP3 [227]; however, this pathway is inhibited by vIRA interaction with 
RIP3 through its RHIM domain [273]. Necroptosis seems to be key to control of mCMV 
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infection, as mice infected with mCMV expressing vIRA with a mutated RHIM domain that 
cannot inhibit necroptosis completely control infection, whereas RIP3-/- mice infected with 
mutant mCMV cannot control the infection [227]. Human CMV infections also inhibit 
necroptosis through a distinct mechanism that acts at an unknown point downstream of MLKL 
activation [274]. 
HSV-1 infection in mice also induces necroptosis. In this case, infected cell protein 6 
(ICP6), a RHIM-domain containing viral protein, binds directly to RIP3 to assemble a signaling 
complex and drive necroptosis [275]. However, in humans, ICP6 also forms complexes with 
RIP3, but instead of driving necroptosis, this disrupts the formation of the necrosomes and 
prevents necroptosis [276, 277]. This fascinating difference between human and mouse 
necroptotic pathways underlines the need for use of appropriate models when studying this 
system. 
There is also evidence that influenza infection is capable of triggering necroptosis in the 
respiratory epithelium, as cIAP2-/- mice died from sublethal doses of influenza due to necroptosis 
[278]. 
Necroptosis is also important in the control of vaccinia virus (VV) infection. RIP3-/- mice 
exhibited reduced inflammation and higher viral titers in response to VV infection, eventually 
succumbing to a sublethal dose [208]. Interestingly, VV encodes a caspase inhibitor [279]; this 
may explain one mechanism by which necroptosis is induced.  
There is also evidence of necroptosis during bacterial infections. Salmonella 
typhimurium induces type I IFN dependent necroptosis in macrophages upon infections; this 
actually leads to impaired control of the infection, as interferon α/β receptor (IFNAR)-/- mice 
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exhibited better control of infection [280]. β-toxin produced by Clostridium perfringens also is 
able to induce a form of cell death that is likely necroptosis [281]. 
1.6.3 Necroptosis in human physiology 
Since the delineation of necroptotic signaling, it has been shown that necroptosis plays an 
important role in diverse human pathologies involving aberrant tissue death. Many diseases of 
the eye involving cell death are mediated by necroptosis. Cone cell degeneration during retinitis 
pigmentosa (RP) is caused by necroptosis, as a RIP3-/- mouse model of RP did not show signs of 
cone cell death [282]. Cell culture models have also shown that oxidative stress induced cell 
death of retinal pigment epithelial cells, characteristic of late-stage age-related macular 
degeneration, is necroptotic in nature [283]. 
There is also evidence of intestinal pathologies caused by necroptosis.  Mouse models 
show that loss of caspase 8 in intestinal epithelial cells leads to high susceptibility to colitis due 
to enhanced necroptosis [284]. Additionally, biopsies of the terminal ileum of patients with 
Crohn’s disease showed increased necroptosis of Paneth cells [284] and children with irritable 
bowel disease show increased protein levels of RIP3 and MLKL and decreased levels of caspase 
8 [285]. 
In addition to these pathologies, there is considerable evidence that other organs 
experience necroptotic cell death that contributes to disease or injury, including the liver [269, 
270, 286] and the skin [287, 288]. Systemic TNFα-mediated shock is also dependent on 
necroptosis [289, 290]. 
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Taken together, the current literature suggests that RIP3-mediated necroptotic cell death 
is a pathway activated downstream of diverse stimuli, including death receptor ligation, PRR 
signaling, and IFN signaling. It is constitutively negatively regulated by caspase 8 and RIP1, and 
release of these regulations can result in spontaneous necroptosis. Mechanistically, necroptosis 
results in phosphorylation of MLKL and insertion of MLKL into membranes to form pores, 
resulting in eventual membrane rupture. This process is relevant in the control of a variety of 
microbial infections, and is active in diverse pathologies involving aberrant cell and/or tissue 
death. 
1.7 AUTOPHAGY 
Macroautophagy (hereafter, autophagy) is an evolutionarily conserved process by which 
cytoplasmic contents are degraded and their components recycled for reuse by the cell [291]. 
Here the mechanisms of autophagic initiation and flux are detailed, the data regarding the source 
of autophagic membranes are explored, and the methods by which autophagy is measured 
experimentally are discussed. Additionally, data surrounding the role of autophagy during 
pathogen infection, specifically CVB infection, are discussed. 
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1.7.1 Mechanisms of Autophagy 
Autophagy can be categorized into selective and non-selective forms, characterized by 
degradation of bulk cytoplasmic contents or targeted degradation of specific organelles and 
cytoplasmic contents, respectively [292]. Selective autophagy is further subdivided into 
categories based on the identity of what is selectively degraded, including mitophagy 
(mitochondria) [293], pexophagy (peroxisomes) [294], and xenophagy (intracellular pathogens) 
[295]. This process has been thoroughly studied in yeast model systems, and many of the 
autophagy related proteins are conserved in mammalian systems [296].  
Constitutive autophagy is important in the maintenance of cell health, and maintenance of 
basal levels of autophagy appears to be especially important in neurons [297]. Additionally, the 
induction of autophagy is an important response to a variety of cell stressors. Starvation is the 
classical stimulus of autophagy, with both glucose starvation [298] and amino acid starvation 
[299] resulting in rapid activation of autophagy through distinct mechanisms. Additional 
circumstances can also lead to the induction of autophagy, including oxidative stress [300], ER 
stress [301], or organellar damage [302].  
In brief, the autophagic process consists of the formation of a phagophore, a double-
membraned structure, which then expands and engulfs cytoplasmic contents. This structure, now 
known as an autophagosome, fuses with a lysosome, a degradative compartment, to effect the 
degradation of its contents. There is a core autophagy machinery that is required for the initiation 
of all subtypes of autophagy. This machinery consists of the unc-51 like kinase (ULK) complex, 
a regulatory complex involved in initiation, the autophagosome-related 9 (Atg9) complex, 
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required for membrane recruitment, the PI3K complex, required for nucleation of the 
phagophore, and ubiquitin-like (Ubl) conjugation systems, required for expansion of the 
phagophore [303]. The source of the membranes that form the phagophore is a key question in 
the field of autophagy research. Much focus has been placed on the ER as a source of 
autophagosome membranes, with mounting evidence that the ER, including ER-mitochondria 
contact points, ER exit sites, and the ER-Golgi intermediate complex (ERGIC), is a major source 
of membranes [304]. However, there is also evidence that other sources, including the Golgi and 
recycling endosomes, may play a role [305]. Once the autophagosome has been established, it 
must then fuse with a degradative compartment, the lysosome. This fusion is mediated by a 
soluble NSF attachment protein (SNAP)- SNAP receptor (SNARE) system [306] requiring the 
interaction of syntaxin 17 on the autophagosome [307] and vesicle-associated membrane protein 
8 (VAMP8) on lysosomes [308]. 
The recruitment of specific cargo into autophagosomes to carry out selective autophagy is 
primarily accomplished through the action of p62, otherwise known as sequestosome 1 
(SQSTM1) [309]. p62/SQSTM1 physically interacts with both ubiquitinated proteins destined 
for autophagosomal degradation and the autophagosomal-membrane associated protein light 
chain 3 B (LC3B) [310]. Other cargo can be targeted to the autophagosome by a similar method 
utilizing different adaptor proteins. 
There are a number of experimental methods by which autophagy can be detected and 
measured. The initiation of autophagy results in the lipidation of LC3B, allowing its association 
with the autophagosomal membrane [311]. This lipidation can be detected by immunoblotting 
the results of a reducing polyacrylamide gel electrophoresis (SDS-PAGE), as non-lipidated 
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LC3B (LC3B-I) is detected at ~18 kD whereas lipidated LC3B (LC3B-II) is detected at ~16 kD 
[312]. Additionally, autophagy can be detected by electron microscopy due to the appearance of 
characteristic double-membraned vesicles [312]. Autophagy can also be detected by measuring 
the accumulation of autophagosomes by immunofluorescence microscopy to detect LC3B or 
p62/SQSTM1 punctae [312]. Finally, autophagic flux, or completion of the autophagic pathway, 
can be detected by the degradation of p62/SQSTM1; this can be measured by examining protein 
levels by immunoblot [312]. Proper application of these techniques is key to productive study of 
autophagic pathways. 
1.7.2 Autophagy and CVB infection 
Autophagy is largely considered an antimicrobial process. Innate immune signaling can induce 
autophagy, and diverse intracellular pathogens are shuttled to autophagosomes for degradation in 
a process known as xenophagy [295]. However, there are certain pathogens, particularly RNA 
viruses, which have evolved to take advantage of autophagy and utilize it to aid in their own 
replication [313]. Here, the ways in which CVB is known to interact with autophagic pathways 
are discussed. 
Blocking autophagy in vitro [314] or in vivo [315] reduces CVB replication. There has 
been much research into the ways in which autophagy is subverted by CVB for its replication. It 
has long been noted that enteroviral replication occurs on membranous structures [316], and that 
enteroviral infection results in massive rearrangement of host membranes to form these 
structures [317]. It has been proposed that autophagic pathways provide the membranes for these 
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viral replication complexes [318, 319], explaining the requirement of autophagy by CVB. 
Whether CVB requires only autophagic initiation or benefits from autophagic flux remains 
unclear. Studies in non-polarized cells have suggested that whereas autophagosome formation 
and initiation of the autophagic pathway is utilized by CVB for replication, autolysosomal fusion 
is dispensable [314]. However, recent studies from our laboratory have shown that in polarized 
endothelial cells, complete flux through the autophagic pathway may be beneficial for CVB 
infection [320]. It is clear, however, that induction of autophagy benefits CVB replication.   
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2.0  UNC93B INDUCES CELL DEATH AND IS CLEAVED BY CASPASES AND AN 
ENTEROVIRAL PROTEASE 
2.1 INTRODUCTION 
Unc93b is an ER-resident transmembrane protein that is required for signaling from endosomally 
localized TLRs as well as TLR5, a cell surface receptor [192-195]. The importance of Unc93b 
and its client TLRs in initiating immune responses to viral infections was underscored when it 
was discovered that children inheriting two autosomal recessive mutant alleles of Unc93b that 
produce a non-functional, truncated version of the protein developed Herpes Simplex 
Encephalitis (HSE), a rare but serious viral encephalopathy, after Herpes Simplex Virus-1 (HSV-
1) infection [321]. An increased risk of HSE after HSV-1 infection is also seen in children with 
autosomal dominant mutations in TLR3 [322], suggesting that the trafficking of TLR3 by 
Unc93b is crucial for the control of HSV-1 infection. Additionally, it was shown that patients 
with SLE had higher levels of Unc93b expressed in immune cells than in healthy control 
patients, suggesting that high levels of Unc93b are responsible for the dysregulated TLR 
signaling known to be associated with SLE pathogenesis [323]. Thus, Unc93b is important in 
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both innate immune defense against pathogens and in the development of autoimmunity in 
humans. 
In addition to TLR-mediated signaling, the induction of cell death is a powerful innate 
immune pathway by which host cells protect themselves from microbial infections. Indeed, many 
components of TLR-mediated signaling also participate in the induction of pro-apoptotic 
signaling in response to viral infections, underscoring the importance of these pathways in host 
defense. For example, TRIF, the TLR3/4 adaptor, potently induces apoptosis via its RHIM 
domain located in its C-terminus [253, 324].  
TLR3 is considered to be the critical TLR in sensing the presence of CVB, an enterovirus 
that is a leading cause of myocarditis. Humans who develop myocarditis after enteroviral 
infections have increased frequencies of SNPs in TLR3 that render them less responsive to TLR3 
ligands [149], and TLR3-/- mice show increased mortality and myocarditis in response to CVB 
infection [147]. These data suggest that TLR3 senses the dsRNA intermediate produced during 
CVB replication, and that this sensing and subsequent activation of innate immune signaling is 
key to the control of CVB infection. Indeed, recent work has shown that Unc93b1LETR/LETR mice, 
which have a loss of function mutation in the gene encoding Unc93b, exhibit increased mortality 
upon CVB-induced myocarditis due to higher viral titers and dysregulation of inflammation in 
these mice [201]. 
CVB utilizes cell death-mediated destruction of the host cell membrane for its egress. 
However, the virus must balance cell death induction precisely during its replication as activating 
cell death prematurely, or by alternative pathways, could inhibit replication and/or induce 
inflammatory signaling. CVB commonly induces apoptosis in many cell types to facilitate its 
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egress [93, 110, 325]. The mechanisms by which CVB modulates cell death signaling are likely 
complex and involve the alteration of many components associated with this pathway. CVB 
commonly alters host cell signaling, including TLR and cell death signaling, by the direct 
cleavage of host proteins by the 2Apro and 3Cpro virally encoded cysteine proteases [104, 174].  
Interestingly, analysis of microarray data [201] using the database for annotation, 
visualization and integraded discovery (DAVID), a bioinformatics tool from the National 
Institute of Allergy and Infectious Diseases (NIAID) [326, 327], from cardiac tissue of wild-type 
mice found that there was a significant enrichment in expression of genes involved in cell death 
as compared to Unc93b1LETR/LETR mice (p=0.0051). Given that Unc93b is directly linked to 
CVB-induced pathogenesis in vivo, we examined whether Unc93b was involved in cell death 
signaling during infection. We found that ectopic expression of Unc93b robustly induced 
apoptosis, and that this induction required its exit from the ER as the H412R mutant of Unc93b 
lacking this function was incapable of inducing cell death. In addition, we found that caspases 
activated by TNFα signaling, or by the induction of TRIF-mediated TLR3 signaling, cleaved 
Unc93b at a single site (position D27) located within its N-terminus. Additionally, we found that 
the CVB-encoded protease 3Cpro also cleaved Unc93b at a single site within 10 amino acids of 
the caspase cleavage site (position Q17). Collectively, these studies point to a previously 
uncharacterized role for Unc93b in the initiation of apoptosis during TLR3 signaling and suggest 
that both host and viral proteases target the N-terminus of Unc93b to alter some aspect of its 
function.   
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2.2 RESULTS 
2.2.1 Expression of Unc93b induces cell death 
The overexpression of several components associated with innate immune signaling, including 
the TLR3 adaptor TRIF, potently induces apoptosis [253, 328, 329]. We found that ectopic 
expression of Unc93b in 293T cells consistently induced significant morphological changes in 
transfected cells, resulting in cell rounding, disruption of cell monolayers, and other signs of cell 
stress/death (Figure 4A). To further investigate these morphological changes, we measured cell 
viability based on quantitation of ATP through a luminescent detection method (Cell Titer Glo) 
and found that Unc93b overexpression significantly decreased cell viability (Figure 4B). 
Additionally, we found that Unc93b expression also enhanced cell death induced upon treatment 
with staurosporine, an apoptosis inducer (Figure 4B). To identify the cell death pathway(s) 
initiated by Unc93b, we determined the impact of Unc93b overexpression on propidium iodide 
(PI) uptake and Annexin V binding by flow cytometry. We found that Unc93b specifically 
induced apoptotic cell death and led to an ~3-fold increase in the levels of PI- and Annexin V-
positive cells. (Figure 4C, 4D). Additionally, we found that the induction of cell death was 
partially sensitive to caspase inhibition, as treatment of cells with the pan-caspase inhibitor 
zVAD-fmk was sufficient to block Unc93b induced morphological changes associated with cell 
death and caused a mild reduction in PI- and Annexin V-positive cells that did not reach 
statistical significance (Figure 4F, 4G, 4H). Of note, the frequency of PI-positive cells was not 
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reduced by zVAD-fmk treatment, suggesting that upon blockage of caspase-dependent pathways, 
alternative pathways may be activated (data not shown). 
The H412R mutant of Unc93b has been well characterized for its inability to bind TLRs 
[196], facilitate TLR signaling [192], or traffic out of the ER [186, 197]. To determine whether 
these functions were also required for the apoptosis-inducing properties of Unc93b, we 
determined the effect of Unc93b H412R expression on apoptosis using the assays described 
above. Importantly, we found that the H412R mutant of Unc93b did not induce morphological 
changes when overexpressed in 293T cells (Figure 4A), did not alter cellular ATP levels 
(Figure 4B), and did not induce apoptosis as assessed by flow cytometry, despite equivalent 
levels of expression (Figure 4C, 4D, 4E). Taken together, these data implicate a previously 
uncharacterized role for Unc93b in the induction of apoptosis and suggest that its ability to 
traffic from the ER is required for this function.  
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Figure 4.  Unc93b expression induces apoptotic cell death. 
(A-H) 293T cells were transfected with WT or H412R Unc93b containing a C-terminal Myc tag (A) 48 hours post-
transfection, differential interference contrast (DIC) images were obtained from live cells. (B) 48 hours post-
transfection, cells were treated with staurosporine for 24 hours and cell death was measured by Cell Titer Glo assay. 
Data shown is an average of 6 experiments. (C) 72 hours post-transfection, cells were stained with Annexin V and 
PI and analyzed by flow cytometry. Data shown are representative of 4 experiments. Cell population was 
determined by gating events on Forward Scatter (FSC) and Side Scatter (SSC). Cells were then gated based on 
Annexin V and PI staining intensities. (D) 48-72 hours post-transfection, cells were stained with Annexin V and PI 
and analyzed by flow cytometry as in 4C, and Annexin V+/PI+ populations were compared. Data shown are 
representative of 4 experiments (E) 293T cells were transfected in parallel with those shown in 4D, lysates were 
harvested and then subjected to immunoblotting with anti-Myc or -GAPDH antibodies. (F) Prior to transfection (1 
hour) cells were treated with zVAD-fmk and then transfected with the indicated constructs for 48 hours (in zVAD-
fmk-containing medium). Approximately 48 hours post-transfection, DIC images were obtained from live cells. (G-
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H) Prior to transfection (1 hour) cells were treated with zVAD-fmk and then transfected with the indicated 
constructs for 72 hours (in zVAD-fmk-containing medium). 72 hours post-transfection cells were stained with 
Annexin V and PI and analyzed by flow cytometry as in 4C. Data shown are representative of 2 experiments (G) or 
average of 2 experiments (H). 
2.2.2 Unc93b is cleaved by caspases 
Because we observed a role for Unc93b in the induction of apoptosis, we next examined whether 
Unc93b is regulated by caspase-mediated cleavage during apoptotic cell death as a negative 
feedback mechanism to attenuate its function in cell death signaling. To do this, we activated 
caspases via TNFα treatment and determined whether this treatment led to the proteolytic 
cleavage of Unc93b. For these studies, we utilized an N-terminal EGFP fusion construct of 
Unc93b overexpressed in 293T cells. We found that activation of caspases through TNFα 
treatment induced the appearance of an ~33 kD N-terminal GFP-fused cleavage fragment of 
Unc93b when assessed by immunoblotting (Figure 5A). The quantity of this cleavage fragment 
was enhanced when cells were treated with TNFα in the presence of the NF-κB inhibitor JSH-23 
(Figure 5A). By immunoblotting, Unc93b appears as a major species band and a high molecular 
weight ‘smear’, consistent with reports that Unc93b is ubiquitinated [330]. Importantly, Unc93b 
cleavage was inhibited by the addition of a pan-caspase inhibitor, zVAD-fmk, confirming the 
role of caspases in this cleavage event (Figure 5A). Caspase activation was confirmed by 
detection of cleaved poly ADP ribose polymerase (PARP), a classical caspase substrate [331] 
(Figure 5A). Using a caspase cleavage site detection algorithm [332], we identified two potential 
caspase cleavage sites (D21 and D27) within the N-terminus of Unc93b that would induce the 
appearance of the ~33kD N-terminal GFP-fused cleavage product by immunoblot. We found that 
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site-directed mutagenesis of D27 to alanine (D27A) completely inhibited the caspase-dependent 
cleavage of Unc93b (Figure 5A). Thus, we conclude that D27 is the only site within Unc93b 
targeted by caspases.  
Sustained signaling through TLR3 can result in caspase-mediated cell death [333]. As 
Unc93b is necessary for TLR3 signaling, we postulated that TLR3-dependent caspase activation 
might also result in Unc93b cleavage via the activation of caspases. To test this, we 
overexpressed the TLR3 adaptor protein TRIF, which induces TLR3 signaling, and found that 
TRIF overexpression resulted in Unc93b cleavage in a caspase dependent manner at residue D27 
(Figure 5B). TRIF-mediated caspase activation has been shown to be dependent on its C-
terminal RHIM domain [253]. To determine whether this domain was required for the TRIF-
induced cleavage of Unc93b, we expressed an N-terminal construct of TRIF lacking the RHIM 
domain (NT) or a C-terminal construct containing the RHIM domain (CT). We found that 
expression of the C-terminus of TRIF alone was sufficient to induce Unc93b cleavage and that 
this cleavage occurred at position D27 as cleavage was absent in the D27A mutant of Unc93B 
(Figure 5C). Collectively, these data show that Unc93b is targeted by cellular caspases at 
position D27 during apoptosis induced by TNFα and by TLR3-TRIF signaling. 
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Figure 5. Unc93b is cleaved by caspases during apoptosis. 
(A) 293T cells were transfected with the indicated eGFP-fused Unc93b construct and 48 hours post-transfection 
cells were treated with TNFα, JSH-23, and Z-VAD-FMK (or mock control) for 18 hours, lysates were harvested and 
subjected to immunoblotting with anti-GFP, -PARP, or -GAPDH antibodies. (B) 293T cells were transfected with 
the indicated eGFP-fused Unc93b constructs and HA- Flag dual-tagged TRIF and treated with zVAD-fmk 6 hours 
post-transfection. Lysates were harvested 48 hours post-transfection and subjected to immunoblotting with anti-
GFP, -PARP, and –GAPDH antibodies. (C) 293T cells were transfected with the indicated eGFP-fused Unc93b and 
Flag-tagged TRIF constructs (Full-length, N-terminal or C-terminal); lysates were harvested 48 hours post-
transfection and subjected to immunoblotting with anti-GFP and -GAPDH antibodies. In all panels, ns denotes 
nonspecific bands. 
2.2.3 Unc93b is cleaved by the CVB virally-encoded protease 3Cpro 
Many viruses induce apoptosis during their infectious life cycles. In some cases, this induction is 
an innate immune response induced by the host cell in order to clear the viral infection whereas 
in other cases, viruses utilize the induction of cell death to promote their egress. Enteroviruses 
such as CVB often induce apoptosis to disrupt the host cell membrane to facilitate egress. 
Because we found that caspases cleaved Unc93b during apoptotic cell death in response to TNFα 
treatment and TRIF signaling, we next assessed whether this cleavage might also occur during 
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viral infection. Using 293T cells overexpressing N-terminal EGFP-fused Unc93b, we detected 
the appearance of an ~30 kD N-terminal GFP-fused cleavage fragment of Unc93b in CVB-
infected cells by immunoblotting (Figure 6A). We found that the D27A mutant of Unc93b was 
not protected from CVB-induced cleavage, suggesting that other viral and/or cellular factors 
were responsible for cleavage of another site(s) within Unc93b (Figure 6C). CVB is known to 
utilize virally encoded proteases to target host proteins [107]. Using an algorithm designed to 
detect the semi-conserved consensus cleavage sites for the two CVB-encoded proteases 2Apro 
and 3Cpro [334], we identified a putative 3Cpro cleavage site in Unc93b at residue Q17, which 
would be predicted to produce an N-terminal GFP-fused fragment consistent with that observed 
during CVB infection. In contrast, Unc93b did not contain any consensus 2Apro cleavage sites. 
We found that overexpression of wild-type (WT) CVB 3Cpro, but not a catalytically inactive 
mutant lacking protease activity (C147A), induced the appearance of the ~30kD N-terminal 
cleavage fragment of EGFP-fused Unc93b (Figure 6B). By performing site-directed 
mutagenesis, we found that 3Cpro specifically targeted residue Q17 in the N-terminus of Unc93b 
as a mutant of this site (Q17A) completely resisted cleavage (Figure 6B). We confirmed that 
Q17 was the sole site responsible for the cleavage of Unc93b during CVB infection by infecting 
293T cells expressing either the Q17A or caspase-resistant D27A Unc93b mutants and assessing 
their cleavage sensitivity during infection. (Figure 6C). These data suggest that although 
caspases are activated during CVB infection, Unc93b is targeted for cleavage by the virally-
encoded 3Cpro CVB protease.  
As TLR3 signaling has been established as an important step in the initiating an immune 
response to CVB, we next assessed the possibility that 3Cpro-mediated cleavage of Unc93b 
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effects its ability to facilitate TLR3 signaling. To do this, we generated a truncation mutant of 
Unc93b missing the first 17 N-terminal amino acids (Unc93bΔ17, schematic Figure 7A), which 
is representative of the C-terminal fragment of Unc93b that remains in the cell following 
cleavage by 3Cpro. We determined the effect of expression of Unc93bΔ17 on IFNβ induction 
downstream of TLR3, an endosomal TLR entirely dependent on Unc93b for its endosomal 
trafficking [186, 196]. We treated HEK293 cells stably expressing TLR3, and transiently 
expressing a firefly luciferase construct downstream of the IFNβ promoter, with poly(I:C), a 
synthetic TLR3 ligand, and examined TLR3 activation in the presence or absence of WT-, Δ17-, 
or H412R-Unc93b by measuring luciferase levels. We found that expression of WT Unc93b 
enhanced TLR3 signaling, whereas Unc93bH412R did not. However, TLR3 signaling upon 
expression of Unc93bΔ17 was not significantly different than WT Unc93b (Figure 6D), 
indicating that the ability of Unc93b to facilitate TLR signaling is not affected by 3Cpro-mediated 
cleavage. Although we observed that expression of Unc93bΔ17 trended towards a lower level of 
TLR3-mediated IFNβ induction than WT Unc93b, this effect was not statistically significant, 
suggesting that any defect in facilitating TLR3 signaling is mild and likely not biologically 
relevant. 
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Figure 6. Unc93b is cleaved by 3Cpro during CVB infection. 
(A) 293T cells transfected with eGFP-Unc93b were infected with CVB (MOI=1). Lysates were harvested 18 hours 
post-infection, then subjected to immunoblotting with anti-GFP, -VP1, and -GAPDH antibodies. (B) 293T cells 
were cotransfected with the indicated eGFP-fused Unc93b construct and Myc-tagged wild-type (WT) or 
catalytically inactive C147A 3Cpro. Lysates were harvested 48 hours post-transfection and subjected to 
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immunoblotting with anti-GFP and -GAPDH antibodies. (C) 293T cells transfected with the indicated eGFP-fused 
Unc93b construct were infected with CVB (MOI=1). Lysates were harvested 16 hours post-infection and subjected 
to immunoblotting with anti-GFP, -VP1, and –GAPDH antibodies. In all panels, ns denotes nonspecific bands. (D) 
HEK293-FlagTLR3 cells were co-transfected with the indicated Unc93b construct containing a C-terminal Myc tag 
and IFNβ luciferase reporter (pIFNβ-fluc) and control renilla  (pRL-null) constructs. Approximately 24 hours post 
transfection, cells were treated with 100ng poly(I:C) for 16 hours.  Luciferase levels were analyzed using the Dual 
Luciferase reporter assay system. Data shown are from a representative experiment. Firefly luciferase levels were 
normalized to renilla luciferase levels and then normalized to the vector transfected mock-treated condition. 
2.2.4 Unc93b cleavage does not affect its localization or trafficking 
We identified two distinct mechanisms of Unc93b cleavage—one dependent on a virally-
encoded protease during viral infection and one induced by cellular caspases. Both of these 
cleavage events sever the N-terminal tail of Unc93b before its first transmembrane domain 
(schematic, Figure 7B). Given that two unrelated proteases cleave Unc93b, we next examined 
the effect of 3Cpro- and caspase-mediated Unc93b cleavage on a hallmark Unc93b function: its 
ability to traffic through the secretory pathway. In addition to the Unc93b∆17 truncation mutant 
described above, we also generated an Unc93b truncation mutant lacking the first 27 N-terminal 
amino acids (Unc93bΔ27, schematic Figure 7A), which is representative of the C-terminal 
fragment of Unc93b that remains in the cell following caspase cleavage. We overexpressed WT 
Unc93b, Unc93bΔ17, Unc93bΔ27, or Unc93bH412R in U2OS cells with EGFP-fused VSV-G, a 
glycoprotein from vesicular stomatitis virus widely used in the study of intracellular trafficking 
[335]. As expected, WT Unc93b efficiently trafficked through the secretory system, as indicated 
by its co-localization with VSV-G in punctate structures (Figures 7C, 7D). However, 
Unc93bH412R failed to localize to these VSV-G positive punctae (Figures 7C, 7D), supporting 
previously published data indicating that Unc93bH412R is incapable of exiting the ER [186, 
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197]. Similar to WT Unc93b, both Unc93bΔ17 and Unc93bΔ27 co-localized efficiently with the 
VSV-G positive punctae (Figures 7C, 7D), indicating that the trafficking of Unc93b is 
unaffected by 3Cpro- and caspase-mediated N-terminal truncations.  
 
Figure 7. Unc93b cleavage does not affect trafficking to endosomes. 
(A) Schematic of Unc93b truncation mutants. (B) Schematic of Unc93b cleavage events. (C,D) U2OS cells were co-
transfected with Venus-fused VSV-G and the indicated Unc93b constructs containing a C-terminal Myc tag. 
Approximately 48-72 hours post-transfection, cells were fixed and then immunostained for Myc and confocal 
microscopy performed (C) and then images analyzed to obtain Pearson’s correlation coefficients (D). 
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2.2.5 Unc93b cleavage does not affect its induction of cell death.  
Because we found that ectopic expression of Unc93b induced apoptosis, we next assessed 
whether the 3Cpro- and/or caspase-induced cleavage of Unc93b would ablate this function. We 
found that Unc93bΔ17 promoted apoptotic cell death at a level comparable to that of WT 
Unc93b as observed morphologically (Figure 8A) and measured by Cell Titer Glo and flow 
cytometric analysis as described previously (Figures 8B-D). In addition, an N-terminal 
truncation mutant lacking the first thirty amino acids (∆30) of Unc93b also induced 
morphological changes consistent with apoptosis, suggesting that the N-terminal cleavage of 
Unc93b by caspases also does not affect this function (Figure 8E). Although the cells used in 
this study (293T) express low levels of endogenous Unc93b, it is unlikely that these endogenous 
levels are sufficient to mask the lack of functionality in the truncation mutants given that ectopic 
expression of Unc93bH412R did not induce apoptotic cell death. 
  57 
 
Figure 8.  Unc93b cleavage does not affect its induction of cell death. 
(A-D) 293T cells were transfected with the indicated Unc93b construct containing a C-terminal Myc tag. (A) 72 
hours post-transfection, differential interference contrast (DIC) images were obtained from live cells. (B) 48 hours 
post-transfection, cell death was measured by Cell Titer Glo assay. Data shown is average of 6 experiments. (C) 72 
hours post-transfection, cells were stained with Annexin V and PI and analyzed by flow cytometry. Data was 
analyzed as described in Figure 4C, gating events on FSC vs. SSC for cell population are not shown here. Data 
shown are representative of three experiments. (D) 48-72 hours post-transfection, cells were stained with Annexin V 
and PI and analyzed by flow cytometry. Data were analyzed as described in Figure 4C, and Annexin V+/PI+ 
populations were compared. Data shown are average of three separate experiments (E) 293T cells were transfected 
with eGFP-fused Unc93b constructs containing a C-terminal Myc tag. 48-72 hours post-transfection, DIC images 
were obtained from live cells. 
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2.3 DISCUSSION 
Unc93b is critical for an effective immune response to diverse pathogens, including CVB, and 
has been associated with the development of autoimmune disease. Despite its important role in 
human health, its function has only recently been uncovered and, accordingly, our understanding 
of Unc93b function has been rapidly expanding in both breadth and depth. Here we show that 
CVB utilizes its virally-encoded 3Cpro cysteine protease to directly target the distal N-terminus of 
Unc93b. We also show that cellular caspases also target this region and cleave Unc93b within 10 
amino acids from the site of 3Cpro cleavage. In addition, we further broaden the known role of 
Unc93b by describing its function in initiating apoptotic cell death pathways and find that the 
H412R mutant of Unc93b is unable to induce cell death.  
Here, we discover a new and important function for Unc93b in the induction of apoptotic cell 
death. As it has been previously shown that genes known to be involved in cell death are 
downregulated in the cardiac tissue of mice expressing a non-functional Unc93b variant [201], it 
is likely that Unc93b is involved in the maintenance of a balance between cell death and cell 
survival under resting conditions. Additionally, cell death induction is critical in the response to 
many intracellular pathogens [336]. Thus, further understanding the role Unc93b is playing in 
cell death helps to broaden the understanding of Unc93b function during initiation of innate 
immune and cell death signaling. Although it remains unclear by what mechanism Unc93b 
initiates apoptosis, it is intriguing that Unc93bH412R is incapable of inducing this pathway. 
Unc93bH412R is incapable of binding TLRs, but the cell type used in our study (293T) does not 
express TLRs at significant levels [337]. Thus, the role Unc93b plays in inducing cell death is 
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most likely independent of its role in TLR trafficking and/or signaling. In addition to its inability 
to bind TLRs, Unc93bH412R also remains localized to the ER [197] and does not localize to 
endolysosomal vesicles. Given the lack of apoptosis induction by Unc93bH412R and its 
retention in the ER, it is possible that Unc93b may be involved in a more general trafficking 
pathway than previously appreciated, and serve to traffic components of apoptotic signaling out 
of the ER.  Although the precise mechanism(s) by which Unc93b induces apoptosis remain to be 
determined, our work indicates that the effect is at least partially mediated by cellular caspases as 
the morphological changes associated with Unc93b-mediated apoptotic cell death are inhibited 
by the pan-caspase inhibitor zVAD-fmk.    
The caspase-mediated cleavage of Unc93b discovered here serves to place Unc93b into the 
broader context of interactions between innate immune proteins and caspases. In recent years, 
caspases have been shown to be closely involved in the regulation of innate immune signaling 
through execution of specific cleavage events. For instance, innate immune signaling upon 
activation of RIG-I, a cytosolic RNA sensor, is dependent on recruitment of RIP1. Caspase 8 
serves to cleave and disable RIP1, providing a negative feedback mechanism to control and 
down-regulate innate immune signaling [338]. Conversely, caspase activation has also been 
reported to be required for activation of innate immune signaling, as NF-κB activation can be 
dependent on caspase 8 activity in certain circumstances [339-341]. Clearly, the role of caspase-
mediated cleavage events is crucial not only in the context of programmed cell death, but also in 
non-apoptotic functions associated with the regulation of intracellular innate immunity. Thus, it 
seems likely that the caspase-mediated cleavage of Unc93b serves to alter its role in some aspect 
of host innate immune and/or cell death signaling.  
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It is of special note that two evolutionarily independent proteases, the virally encoded 3Cpro 
cysteine protease of CVB and host caspases, target Unc93b for cleavage within the same 10 
amino acid N-terminal region. As caspase activation results in the cleavage of Unc93b at residue 
D27, we initially suspected that this cleavage event would serve to modulate the proapoptotic 
signaling role of Unc93b. However, we found that Unc93bΔ30 was fully capable of inducing cell 
death under the conditions we tested. Although we found the truncated versions of Unc93b 
produced by both 3Cpro and caspases to be capable of performing the known functions of 
Unc93b, we suspect that this important and under-characterized protein has more functions than 
previously elucidated, and it is likely that these cleavage events serve to hinder one of those 
functions. We eagerly anticipate the advancement of the field of research surrounding Unc93b 
and expect that soon these cleavage events will be placed in their proper functional context. 
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3.0  RIP3 IS REQUIRED FOR CVB INFECTION 
3.1 INTRODUCTION 
Coxsackievirus B3 (CVB), a member of the enterovirus family, is transmitted via the fecal-oral 
route and encounters the polarized intestinal epithelial cells (IECs) lining the gastrointestinal 
tract early in infection. Despite serving as the primary cellular portal for CVB entry, very little is 
known regarding the specific molecular events that regulate CVB replication in and egress from 
the intestinal epithelium. 
An important event in CVB pathogenesis is the induction of host cell death. CVB is a 
lytic virus and possesses few mechanisms for progeny release other than induction of cell death 
and subsequent destruction of the host cell membrane. The induction of cell death signaling by 
CVB in an infected cell must be precisely controlled as activating cell death prematurely or 
aberrantly could inhibit replication and/or induce inflammatory signaling. Whereas CVB induces 
apoptosis in non-polarized cells [93] we have shown that CVB-infected polarized IECs undergo 
calpain-mediated necrosis, which is required for viral egress [80]. These results suggest that the 
cellular factors that facilitate and/or restrict CVB replication in polarized IECs may be unique to 
these specialized cells.  
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In addition to direct lysis of an infected cell, CVB may also egress via microvesicles that 
are associated with markers of autophagy [81]. Autophagy is an evolutionarily conserved process 
that can be induced by a variety of cell stressors, including viral replication, to promote cell 
survival. Autophagy begins with the formation of an isolation membrane (which can be provided 
by an array of cellular organelles [305]) to form the characteristic double-membraned vesicle 
called the autophagosome (AP). Once formed, APs can fuse with endosomes to form 
amphisomes [342], and APs or amphisomes can fuse with lysosomes to form autolysosomes, 
wherein the degradation of many AP-associated components (and any factors they may interact 
with) by lysosomal hydrolases occurs. Completion of this process and degradation of any 
autophagosomal cargo is referred to as autophagic flux [312]. CVB replication is dependent on 
the induction of autophagy and the inhibition of this process both in vitro [314, 320] and in vivo 
[315] greatly reduces viral replication. Thus, CVB may rely on autophagy at two distinct stages 
of the viral life cycle—for the formation of double membrane replication organelles and possibly 
for viral egress in microvesicles. Whereas enteric bacterial pathogens are known to manipulate 
autophagy in polarized IECs [343], it is unknown whether CVB also manipulates the autophagic 
pathway in these cells. 
In order to identify host cell factors that promote and/or restrict CVB replication, we 
previously performed genome-scale RNAi screening in polarized endothelial cells [152]. By 
applying this approach, we identified a number of previously uncharacterized host cell factors 
involved in various pathways involved in CVB replication [60, 344]. However, as this initial 
screening was conducted in polarized endothelial cells, it did not provide any information on the 
specific host cell factors involved in CVB replication in polarized IECs. In the current study, we 
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conducted additional RNAi screening to identify factors required for CVB replication in IECs. 
Together, these screens provide an unbiased comparison of the gene products necessary for CVB 
infection of both epithelial and endothelial barriers. In the current study, we performed RNAi 
screening in IECs and identified receptor-interacting serine/threonine-protein kinase 3 (RIP3) as 
a gene product whose depletion restricted CVB replication. RIP3 is a nonreceptor 
serine/threonine kinase required for necrotic cell death signaling downstream of tumor necrosis 
factor receptor (TNFR) and pattern recognition receptor ligation. However, although RIP3 has 
been associated with the induction of programmed necrosis (‘necroptosis’) in response to TNFα, 
we found that RIP3 regulates CVB replication independently of its role in cell death signaling 
and instead identify a previously uncharacterized role for RIP3 in the regulation of autophagy. 
We show that RIP3 expression is restricted to many polarized IEC cell lines and that RNAi-
mediated silencing of its expression in these cells restricts an early post-entry event associated 
with CVB replication. In addition, we show that IECs lacking RIP3 exhibit defects in autophagy 
and autophagic flux and are unable to survive nutrient deprivation. Furthermore, RIP3 interacts 
with p62/SQSTM1, an adaptor protein that links cargo destined for degradation to APs, and is 
degraded upon serum starvation. Interestingly, we also show that the CVB virally-encoded 
cysteine protease 3Cpro proteolytically cleaves RIP3 to generate two RIP3 fragments, neither of 
which are capable of necrotic cell death signaling, but one of which retains its capacity to 
associate with p62/SQSTM1. Thus, our current study not only identifies RIP3 as a host cell 
factor specifically required for CVB replication in polarized IECs, but also points to a direct role 
for RIP3 in the regulation of autophagy.  
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3.2 RESULTS 
3.2.1 RIP3 facilitates CVB infection in intestinal epithelial cells 
In order to identify genes required for CVB infection of IECs, we performed a genome-scale 
RNAi screen in Caco-2 cells (schematic, Figure 9A). Pathway analysis of the gene products 
identified as required for CVB infection in IECs revealed enrichment of several pathways, 
including cell death and survival (p=5x10-5), molecular transport (p=9.5x10-5), protein trafficking 
(p=9x10-5), and lipid metabolism (p=5.6x10-4). Our screening identified RIP3 as a gene product 
whose depletion significantly reduced CVB replication (robust z score of -2.08), which was 
confirmed in secondary follow up studies (Figure 9B). In addition, we confirmed that RNAi-
mediated knockdown of RIP3 reduced CVB infection in HT29 cells, an independently derived 
IEC line (Figure 9C), and also found that CVB replication was restricted in HT29 cells stably 
expressing an shRNA targeting RIP3 (HT29shRIP3) (Figure 9D, 9E). In contrast, vesicular 
stomatitis virus (VSV) infection was significantly enhanced in HT29shRIP3 cells, indicating that 
RIP3 may be an enterovirus or CVB specific pro-viral factor (Figure 9D, 9E). Notably, 
treatment of cells with the RIP1 inhibitor necrostatin-1 did not restrict CVB replication in HT29 
cells, suggesting that RIP3 may be acting independently of RIP1 to positively regulate CVB 
infection (Figure 9F).  
Because RNAi-mediated knockdown of RIP3 restricted CVB infection in IEC cells, but 
its silencing had no effect on CVB infection in polarized endothelial cells by RNAi screening 
[152], we next examined the expression of RIP3, as well as RIP1, in a panel of cell lines by 
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immunoblotting. We found that every IEC cell line tested (Caco-2 (subclone BBE or ATCC), 
HCT116, HT-29, and T84) expressed RIP3, whereas a diverse panel of non-IEC lines (human 
brain microvascular endothelial cells (HBMEC), HEK293, HeLa, HT1080, and U2OS) did not 
(Figures 9G, 9H). In contrast, all cell lines expressed RIP1. Because we found that silencing of 
RIP3 in IECs restricted CVB replication, we next determined whether overexpression of RIP3 in 
HeLa cells, which do not endogenously express RIP3 (Figure 9G), would alter CVB replication. 
We found that induction of RIP3 in HeLa cells stably expressing a tetracycline inducible RIP3 
expression vector had little effect on CVB replication (Figure 9I), although we did observe a 
significant reduction in RIP3 expression levels upon CVB infection (Figure 9I, inset).  
Taken together, these data imply that RIP3 is a specific regulator of CVB replication in 
polarized IECs.  
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Figure 9. RIP3 facilitates CVB Infection in intestinal epithelial cells. 
(A) Schematic depicting genome-scale RNAi screening in Caco-2 cells. (B) Caco-2 cells transfected with siRNA 
targeting RIP3 (RIP3si) and a control scrambled sequence (CONsi) were infected with CVB (5 PFU/cell) for ~8 
hours and then immunostained for VP1 (green). DAPI-stained nuclei are shown in blue. Infection (%) is shown in 
white text at low right. Representative images from four independent experiments are shown. (C) HT29 cells 
transfected with siRNA targeting RIP3 or a control scrambled sequence were infected with CVB (0.5 PFU/cell) for 
24 hours. Shown are viral RNA levels as assessed by RT-qPCR and averaged from three independent experiments. 
(D-E) WT HT29 or HT29shRIP3 cells infected with CVB (3 PFU/cell) or GFP-VSV (1 PFU/cell) for ~16hrs. 
Infected cells were analyzed for infection by either immunofluorescence microscopy to detect CVB VP1 or GFP-
tagged VSV (D) or RT-qPCR to detect viral RNA (E). Inset in panel (E) shows immunoblotting for RIP1 (in green) 
and RIP3 (in red) in wild-type HT29 or HT29shRIP3 cells. Data shown are representative of at least 3 independent 
experiments. (F) Wild-type or shRIP3 HT29 cells were infected with CVB (1 PFU/cell) for ~16 hrs in the absence 
(mock) or presence of necrostatin-1 (Nec-1) and viral RNA levels were measured by RT-qPCR. (G-H) The indicated 
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cell lines were grown to confluence, then lysed and analyzed for RIP1 and RIP3 expression by immunoblotting (G), 
RIP1 is shown in red and RIP3 is shown in green, or RT-qPCR (H), data are shown as fold over RIP3 expression in 
HBMEC. (I) HeLa-RIP3 Tet-Inducible cells with or without tetracycline were infected with CVB (0.5 PFU/cell) for 
8 hours followed by immunofluorescence microscopy to detect CVB VP1. Shown is the percent infection 
normalized to untreated control cells. Data shown are an average of 3 independent experiments. Inset, HeLa-RIP3 
Tet-Inducible cells with or without tetracycline were lysed and immunoblotted for RIP3 expression performed to 
confirm RIP3 protein expression upon tetracycline treatment. GAPDH (bottom) is included as a loading control.  
3.2.2 RIP3 silencing reduces CVB replication prior to viral egress 
We previously showed that polarized IECs undergo necrotic cell death in response to CVB 
infection whereas non-IECs undergo apoptosis and that necrotic cell death is required in IECs for 
viral egress [80]. Given that RIP3 expression has been associated with necrotic cell death in 
response to TNFα treatment [206-208], and was required for CVB replication in IECs, we next 
determined whether the decrease in CVB replication observed by RNAi silencing occurred early 
in the virus life cycle or could be attributed to deficiencies in viral egress due to alterations in 
necrotic cell death. To do this, we performed a time course of CVB infection and assessed the 
levels of vRNA in HT29 cells transfected with a control or RIP3 targeting siRNA. Surprisingly, 
we found that RNAi-mediated knockdown of RIP3 led to dramatic reductions of vRNA by as 
early as 4 hours post-infection (p.i.) (Figure 10A) suggesting that the reduction in vRNA could 
not be directly attributed to late stages of the viral life cycle (such as egress, which occurs 
between 8 and 12 hours p.i., Figure 10B). 
  68 
3.2.3 RIP3 is not required for CVB entry into intestinal epithelial cells 
Because we found that silencing of RIP3 expression impacted CVB vRNA levels early in 
infection (between 2-4hrs p.i.), we next directly tested whether RIP3 plays a role in CVB entry 
into IECs. In order to address this question, we performed a neutral red (NR) CVB infection 
assay. When propagated in the presence of NR (to generate NR-CVB), the virus becomes 
photosensitive due to damage of the viral RNA induced by photon emission from NR upon 
illumination, thus inhibiting further replication. However, once NR-CVB has entered the cell and 
uncoated, the virus becomes light insensitive due to dilution of the neutral red dye in the 
cytoplasmic compartment, thus preventing photon-mediated damage (schematic, Figure 10C) 
[345]. HT29 cells transfected with a control or RIP3 siRNA were infected with NR-CVB under 
dark and illuminated (light) conditions. As expected, we found that both control siRNA- and 
RIP3 siRNA-transfected-cells exposed to light at 0hrs p.i. (prior to entry and uncoating), were 
extremely photosensitive and exhibited very low levels of CVB replication (Figure 10D). In 
addition, we found that cells transfected with RIP3 siRNA and infected in the dark exhibited a 
reduction in CVB vRNA levels, confirming the role of RIP3 as a positive regulator of CVB 
infection (Figure 10D). Importantly, we found that light exposure at 2hr p.i. (allowing sufficient 
time for entry and uncoating to occur) did not further reduce CVB infection levels in cells 
transfected with siRIP3 compared to cells infected in the dark (Figures 10D), indicating that 
entry of CVB in IECs was not delayed or restricted by RNAi-mediated RIP3 knockdown.  
  69 
 
Figure 10. RIP3 silencing restricts CVB replication prior to viral egress but is not required for viral entry.  
(A) HT29 cells transfected with siRNA targeting RIP3 or a control scrambled sequence were infected with CVB 
(0.5 PFU/cell) for 2-12 hours and viral RNA levels determined by RT-qPCR at the indicated times.  Data shown are 
representative of 3 independent experiments (4-12 hours p.i.) or average of 3 independent experiments (2 hours p.i.)  
(B) HT29 cells transfected with siRNA targeting a control scrambled sequence were infected with CVB (0.5 
PFU/cell) for 4-24 hours followed by assessment of viral titres by plaque assay. (C) Schematic depicting NR-CVB 
replication assay. (D) HT29 cells transfected with siRNAs targeting RIP3 or a control scrambled sequence were 
infected with NR-CVB (10 PFU/cell) as described in (C) and infection determined by immunofluorescence 
microscopy to detect VP1. Data shown are displayed as percent infection and are representative of 3 independent 
experiments.  
3.2.4 RIP3 regulates autophagy in intestinal epithelial cells 
As RIP3 was not required for CVB entry into IECs, we reasoned that RIP3 must be required for 
a viral and/or cellular event that takes place between 2 and 4hrs p.i., as we found similar levels of 
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CVB vRNA at 2hrs p.i., but alterations in vRNA by 4hrs p.i. (Figure 10A). CVB, like many 
positive-stranded RNA viruses, assembles viral replication complexes on scavenged host-cell 
membranes. These host-cell membranes can be derived from diverse locations within the cell, 
but there is evidence to support a prominent role for autophagy in the generation of CVB viral 
replication complexes [318]. Given that our data suggested a role for RIP3 in an early post-entry 
event associated with CVB replication, we examined whether RNAi-mediated knockdown of 
RIP3 impacted nutrient depletion-induced autophagy and/or interfered with CVB-induced 
autophagy. First, we investigated the impact of RIP3 silencing in IECs under basal states and in 
cells subjected to serum starvation, which induces the canonical form of autophagy 
(macroautophagy). We observed a pronounced loss of cell viability in HT29shRIP3 cells 
subjected to serum starvation compared to wild-type controls, suggesting that these cells are 
unable to survive periods of starvation due to alterations in autophagy (Figures 11A, Appendix 
B1A). In addition, we found that knockdown of RIP3 increased the basal levels of p62 as 
assessed by immunoblotting (Figures 11B, 11C) and led to an accumulation of large p62-
positive punctae as assessed by immunofluorescence microscopy (Figures 11D, 11E), but no 
change in the number of punctae (Appendix B1B). Additionally, we noted an accumulation of 
amphisome-like compartments in untreated HT29shRIP3 cells when compared to wild-type 
HT29 cells by transmission electron microscopy (TEM) that resembled the accumulation 
observed in wild-type HT29 cells treated with Bafilomycin-A1 (BafA1) (Figures 11F, 11G, 
Appendix B1C), which prevents the maturation of autolysosomes and thereby the degradation of 
any contents therein. These data suggest that RIP3 may regulate an aspect of autophagic flux that 
occurs following initiation/induction. In support of this, silencing of RIP3 expression did not 
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block conversion of LC3B-I to LC3B-II, a hallmark of autophagy initiation, upon serum 
starvation (Appendix B1D).  
Next, we determined whether loss of RIP3 impacted CVB-induced autophagy. We found 
that RIP3 knockdown in IECs did not prevent conversion of LC3B-I to LC3B-II in response to 
CVB infection, but inhibited the degradation of p62/SQSTM1, an LC3B-binding protein that 
becomes degraded upon flux through the autophagic pathway (Figure 11H).  To prevent the 
degradation of LC3B via autophagic flux, cells were also treated with BafA1. Interestingly, 
LC3B-II levels were enhanced upon RIP3 knockdown, suggesting a defect in post-initiation 
autophagic flux in the absence of RIP3 (Figure 11H). We also observed the accumulation of 
LC3B-II during the course of CVB infection in HT29shRIP3 cells when compared to WT HT29 
cells (Appendix B1E). Collectively, these data support a direct role for RIP3 in the regulation of 
a post-initiation step of autophagic flux in IECs and suggest that the decrease in CVB replication 
in IECs lacking RIP3 may be related to alterations in this pathway.  
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Figure 11. RIP3 is required for autophagic flux in intestinal epithelial cells. 
(A) Transmission electron micrographs of WT HT29 or HT29shRIP3 cells grown to confluence in 12 well plates 
were subjected to serum starvation (SS) in Hank’s Buffered Saline Solution for 9 hours. Black square denotes 
zoomed image shown below. * indicates nuclei of nonviable cells. (B-C) HT29 cells were transfected with siRNAs 
targeting RIP3 or a control scrambled sequence and immunoblotted for p62 (top) and RIP3 (middle). GAPDH 
(bottom) is included as a loading control. Shown are two replicates immunoblotted in parallel, non-adjacent lanes 
from the same gel are separated with a black bar (B). Densitometry was performed and averaged from three 
independent experiments and is shown as the fold change in p62 expression normalized to control siRNA (C). (D-E) 
HT29 cells transfected with siRNA targeting RIP3 or a control scrambled sequence were analyzed by 
immunofluorescence microscopy for p62. Representative images are shown (D) and punctae size was quantified 
from at least 28 individual cells per condition (E). (F-G) Transmission electron micrographs of WT HT29 or 
HT29shRIP3 cells are shown, black arrows denote amphisomes, hatched box denotes zoomed image shown in inset 
(F). Number of amphisomes per cell under mock or Bafilomycin A1-treated conditions for 5 hours were quantified 
(G). (H) HT29 cells transfected with siRNAs targeting RIP3 or a control scrambled sequence were infected with 
CVB for 7 hours. 2 hours p.i. cells were mock- or Bafilomycin A1-treated. Following infection (with or without 
BafilomycinA1 treatment), cells were lysed and immunoblotted for LC3B (top) and RIP3 (middle). GAPDH 
(bottom) is included as a loading control. Densitometry was performed to obtain a ratio of LC3B-II/LC3B-I and is 
shown below. 
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3.2.5 RIP3 interacts with p62 
p62 associates with LC3B, is localized in the internal compartment of the autophagosome, and is 
thus degraded by autophagic flux [310]. p62- and other LC3B-associated proteins can bind to 
cargo proteins that become internalized into APs and are degraded by autophagic flux [346]. 
Surprisingly, we found that similar to p62, RIP3 protein levels were diminished upon serum 
starvation of IECs (Figures 12A, 12B), suggesting that RIP3 may be incorporated into APs 
through a physical association with a component of the autophagic pathway such as p62. Indeed, 
we found that ectopically expressed RIP3 co-immunoprecipitated with endogenous p62 in 293T 
cells (Figure 12C), which do not express any endogenous RIP3 (Figure 12A). This association 
was not disrupted by mRFP-LC3B, suggesting that RIP3 does not compete with LC3B for p62 
association (Figure 12C).  These findings are consistent with a recent publication that suggested 
an association between RIP3 and p62 [347]. Additionally, we found that endogenous RIP3 co-
immunoprecipitated with endogenous p62 in HT29 IECs (Figure 12D). Taken together, these 
data suggest that RIP3 is required for autophagy in IECs, and this role may be facilitated by its 
physical association with p62. 
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Figure 12. RIP3 associates with p62. 
(A-B) HT29 cells in nutrient rich (Ctrl) or depleted (SS) conditions for 12 hours were immunoblotted for RIP3. 
Control lysates are also immunoblotted in Figure 11B. (A). Densitometry was performed and is representative of 
eight independent experiments (B). (C) 293T cells ectopically expressing GFP-tagged RIP3 and/or RFP-tagged 
LC3B were lysed, subjected to immunoprecipitation for p62, and then immunoblotted for RIP3 (top). In parallel, 
whole cell lysates were immunoblotted for RIP3 (middle) and RFP (bottom) to control for protein loading and 
transfection efficiency. (D) HT29 cells grown to confluence were lysed, subjected to immunoprecipitation for p62, 
and then immunoblotted for RIP3 (top). In parallel, whole cell lysates were immunoblotted for RIP3 (middle) and 
GAPDH (bottom) to control for protein loading. Data shown are representative of 3 experiments. 
3.2.6 The CVB-encoded cysteine protease 3Cpro cleaves RIP3 
CVB is known to extensively interact with host cell pathways to antagonize them through 
various mechanisms [107, 348]. One way in which CVB alters its host cell environment is 
through the activity of two virally-encoded proteases, 2Apro and 3Cpro. These proteases are 
required for both processing the viral polypeptide and cleaving a wide variety of host proteins to 
manipulate diverse processes from translation to innate immune signaling to cell death pathways 
[107, 348]. Although we found that RIP3 was involved in the facilitation of CVB replication in 
IECs by promoting autophagy, RIP3 is also a key component in the pro-inflammatory necrotic 
cell death pathway, which may be detrimental to CVB replication. Additionally, we observed a 
reduction in RIP3 expression levels upon CVB infection in HeLa cells overexpressing RIP3 
(Figure 9G). Therefore, we determined whether the loss of RIP3 expression in response to CVB 
infection was a direct result of CVB-mediated proteolytic cleavage. We analyzed the primary 
protein sequence of RIP3 for the presence of consensus cleavage sites for 2Apro or 3Cpro [334] 
and found that there were two possible cleavage sites for 3Cpro located at Q134 and Q430 of 
RIP3 (schematic, Figure 13A). Indeed, CVB infection of 293T cells ectopically expressing RIP3 
resulted in a cleavage of RIP3 as detected by immunoblotting (Figure 13B). Cleavage of RIP3 in 
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293T cells was also observed upon ectopic expression of 3Cpro, but not when a catalytically 
inactive 3Cpro mutant (3Cpro C147A) was expressed (Figure 13C), implicating 3Cpro in the 
cleavage of RIP3 during CVB infection. By mutating the consensus 3Cpro cleavage sites of RIP3, 
we found that mutation of residue Q430 resulted in complete blockage of CVB- and 3Cpro 
expression-mediated RIP3 cleavage (Figures 13D, 13B), indicating that 3Cpro-mediated cleavage 
occurs exclusively after RIP3 Q430.  
Interestingly, 3Cpro-mediated cleavage of RIP3 after residue Q430 cleaves RIP3 in close 
proximity to its RHIM domain, a protein-protein interaction motif necessary for recruitment to 
cell death signaling complexes for the induction of necrosis (schematic, Figure 13A). Given this, 
we investigated the function of the CVB-induced cleavage fragments of RIP3 that contain either 
the kinase domain (RIP3NT) or the RHIM domain (RIP3CT). First, we assessed the localization of 
these fragments in U2OS cells, which do not express endogenous RIP3 (Figure 9F). Upon 
ectopic expression, we found that RIP3NT localized diffusely throughout the cytoplasm, whereas 
RIP3CT localized either to punctate structures that resembled those observed upon expression of 
full length RIP3 or to the nucleus (Figure 13E). 
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Figure 13. The CVB-encoded cysteine protease 3Cpro cleaves RIP3 
(A) Schematic depicting RIP3 domains, consensus 3Cpro cleavage sites (in red), and fragments generated by CVB 
infection. (B) 293T cells ectopically expressing Flag-tagged WT or Q430A RIP3 were infected with CVB (2 
PFU/cell) for 9 hours followed by immunoblotting for RIP3 (top), VP1 (middle), and GAPDH (bottom). (C) 293T 
cells ectopically expressing Flag-tagged RIP3 and Myc-tagged WT or C147A 3Cpro were lysed and lysates were 
immunoblotted for Flag(top), Myc (middle), and GAPDH (bottom). (D) 293T cells ectopically expressing Flag-
tagged WT, Q430A, Q134A, or Q134A/Q430A RIP3 and GFP-tagged WT or C147A 3Cpro were lysed and lysates 
were immunoblotted for Flag (top), GFP (middle), and GAPDH (bottom). Grey arrow indicates RIP3 cleavage 
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fragment (B-D). (E) Confocal micrographs of U2OS cells transiently transfected with GFP-tagged RIP3, RIP3NT, or 
RIP3CT. 
3.2.7 3Cpro-mediated cleavage fragments are incapable of inducing necrotic cell death 
The formation of the RIP1-RIP3 complex (termed the ‘necrosome’) is mediated by the RHIM 
domains present in both molecules and is required for the induction of necroptosis downstream 
of TNFα [349]. Consistent with the RHIM-dependent role of RIP3 in the formation of 
RIP1/RIP3 necrosomes, we found that RIP3CT co-immunoprecipitated with RIP1, whereas 
RIP3NT did not (Figure 14A). In addition to its role in necrotic signaling, RIP1 is also an 
essential component of pro-survival NF-κB signaling. However, unlike RIP1, RIP3 acts a 
negative regulator of NF-κB signaling, which is attributed to the formation of a RIP1-RIP3 
complex that interferes with the association of RIP1 with upstream signaling components [350]. 
Because we found that RIP3CT interacted with RIP1, we determined whether this fragment 
retained the ability of full-length RIP3 to suppress RIP1-mediated NF-κB signaling. Strikingly, 
we found that ectopic expression of RIP3NT and RIP3CT significantly increased RIP1-mediated 
NF-κB signaling in 293T cells as measured by a luciferase reporter fused to the NF-κB promoter 
(Figure 14B), suggesting that the 3Cpro-generated fragments of RIP3 act as positive regulators of 
RIP1-mediated NF-κB signaling. 
 Given the role of RIP3 in necrotic signaling, we next assessed the ability of either 
RIP3NT or RIP3CT to mediate cell death signaling. Unlike full-length RIP3, we found that 
expression of RIP3CT was incapable of inducing necrosis as determined by the nuclear release of 
HMGB1 (Figure 14C) despite its localization into punctate structures and co-
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immunoprecipitation with RIP1. Similarly, RIP3NT expression had no effect on HMGB1 nuclear 
release (Figure 14C). Although we found that expression of RIP3NT and RIP3CT did not induce 
necrosis, we noted that cells ectopically expressing RIP3CT exhibited classic signs of cell death 
and distress, including cell rounding and disruption of the cell monolayer (data not shown). 
Therefore, we examined levels of cell death in 293T cells ectopically expressing full length 
RIP3, RIP3NT, or RIP3CT by propidium iodide (PI) uptake as measured by flow cytometry. We 
found that ectopic expression of full-length RIP3 and RIP3CT, but not RIP3NT, led to the 
enhanced uptake of PI, consistent with an induction of cell death (Figure 14D). Thus, although 
RIP3CT is incapable of inducing necrotic cell death, these results suggest that this fragment 
potently induces a non-necrotic form of cell death. Taken together, these data suggest that the 
cleavage of RIP3 by 3Cpro directly alters the ability of RIP3 to induce necrotic cell death 
signaling while promoting an alternative non-necrotic cell death pathway as well as enhanced 
NF-κB signaling. This suggests that CVB actively manipulates the balance of cell death and cell 
survival signaling pathways in infected host cells through the cleavage of RIP3. 
3.2.8 The C-terminal fragment of RIP3 generated by 3Cpro cleavage retains its ability to 
bind p62 
Our data implicate RIP3 as both a pro-viral regulator of CVB replication due to its involvement 
in autophagy and an antiviral regulator given its role in necrosis and targeting by 3Cpro.  We 
found that the targeting of RIP3 by 3Cpro inhibited its ability to function in necrotic cell death 
signaling. To determine whether this cleavage would also impact its ability to function in 
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autophagy, we determined whether 3Cpro-generated RIP3 fragments were still capable of 
associating with p62. We found that RIP3CT interacted with p62 to similar levels as full-length 
RIP3, whereas RIP3NT exhibited little to no association (Figure 14E). Interestingly, we also 
found that a kinase inactive RIP3 mutant described previously (RIP3K50A) [351] also associated 
with p62, and appeared to do so more efficiently than did wild-type RIP3 (Figure 14E), 
suggesting that the association of RIP3 with p62 may be transient and may be mediated by a 
RIP3-dependent phosphorylation event.  These data suggest that the 3Cpro-mediated cleavage of 
RIP3 abrogates its ability to function in necrotic cell death signaling, but likely does not impact 
its ability to mediate autophagic flux. 
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Figure 14. 3Cpro-mediated cleavage of RIP3 alters host cell signaling pathways. 
(A) 293T cells transfected with vector or GFP-tagged RIP3, RIP3NT, or RIP3CT  and HA-tagged  RIP1 were lysed, 
subjected to immunoprecipitation for GFP, and immunoblotted for RIP1 (top) or GFP (middle). In parallel, whole 
cell lysates were immunoblotted for RIP1 to control for protein loading. (B) 293T cells were co-transfected with 
HA-tagged RIP1, GFP-tagged RIP3, RIP3NT, or RIP3CT, NF-κB promoted firefly luciferase, and a control renilla 
luciferase. Luciferase activity was assessed with the dual luciferase reporter kit. Data shown are representative of 3 
independent experiments. (C) HeLa cells transfected with GFP-tagged RIP3, RIP3NT, or RIP3CT were fixed, 
permeabilized, and HMGB1 localization was determined by immunofluorescence microscopy. White arrows 
indicate nuclei of interest. (D) 293T cells transfected with GFP-tagged RIP3, RIP3NT, or RIP3CT were analyzed for 
propidium iodide (PI) uptake by flow cytometry. Data shown are representative of 3 experiments. (E) 293T cells 
transfected with GFP-tagged RIP3, RIP3K50A, RIP3NT, or RIP3CT were lysed and subjected to immunoprecipitation 
for p62, then immunoblotted GFP (top). In parallel, whole cell lysates were subjected to immunoblotting for GFP 
(middle) and GAPDH (bottom) to control for protein loading; ns=non-specific band. 
3.3 DISCUSSION 
Here we show that RIP3 positively regulates CVB infection. Our data suggest that RIP3 
contributes to the formation of CVB replication organelles via its IEC-specific regulation of 
autophagy. Strikingly, we also found that once CVB establishes its replication and produces 
significant levels of 3Cpro, the protease directly targets RIP3 for proteolytic cleavage. The CVB-
mediated cleavage of RIP3 dampens its ability to promote necrotic cell death while driving pro-
survival NF-κB signaling. Additionally the C-terminal fragment of RIP3 remains associated with 
p62/SQSTM1. In this way, CVB manipulates the function of RIP3 in a targeted way to enhance 
its own replication at both early and late stages of the viral life cycle (schematic, Figure 15).  
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Figure 15. Schematic depicting the role of RIP3 during CVB infection. 
Approximately 2-4 hours post-infection, RIP3 contributes to the establishment of viral replication factories (green 
dashed arrows) through its role as a positive regulator of autophagy. Later in infection (>4hrs p.i., black dashed 
box), large amounts of the viral protease 3Cpro are produced, leading to the cleavage of RIP3 into two distinct 
cleavage fragments, RIP3NT and RIP3CT. These fragments are incapable of inducing necrosis, but do enhance RIP1-
mediated NF-κB signaling, and RIP3CT retains its ability to associate with RIP1 and p62/SQSTM1 and leads to a 
non-necrotic form of cell death. 
 
Since the identification of RIP3 as a key regulator of necrotic cell death, RIP3 has been 
implicated in myriad disease processes. RIP3-mediated necrotic cell death is responsible for the 
destruction of cone cells in retinitis pigmentosa [282], hepatocyte toxicity in acetaminophen 
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overdose [269], and is linked to the destruction of the polarized intestinal epithelium experienced 
in inflammatory bowel disease [242, 285]. Additionally, RIP3-mediated necrosis is responsible 
for cell death upon infection with several DNA viruses including herpes simplex virus 1 [275], 
vaccinia virus [208], and murine cytomegalovirus [227], as well as bacterial infections [280]. We 
have shown previously that necrotic cell death pathways are activated in polarized IECs upon 
CVB infection [80]. Our data now show a positive correlation between necrotic cell death upon 
CVB infection and RIP3 expression. However, further investigation is required to conclusively 
delineate what role RIP3 may play, if any, in the induction of CVB-induced necrotic signaling in 
IECs.  
Our findings suggest a functional link between RIP3 and autophagy. Autophagy is a 
cellular pathway that serves to promote cell survival upon conditions of cellular stress including 
starvation and organelle damage. Indeed, inhibition of autophagy upon nutrient depletion leads to 
accelerated cell death [352]. However, there have been many reports of high levels of autophagy 
accompanying cell death [353], and a subset of cases in which cell death is actually dependent 
upon autophagy [354-356]. One such case is blockade of caspase-8, which induces autophagic 
cell death in L929 cells [356]. Additionally, loss of cell viability upon caspase-8 inhibition in 
L929 cells was later shown to be dependent on RIP3 [241]. Though this loss of viability was 
initially assumed to be due to the role of RIP3 in necroptotic cell death, it is possible that 
inhibition of caspase 8, a known negative regulator of RIP3, in these scenarios may cause an 
increase in RIP3-dependent autophagic flux, resulting in autophagic cell death. 
The relationship between host cell autophagy and viral pathogens is complex. Autophagy 
can serve as an antiviral defense for the host cell, degrading intracellular pathogens and 
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preventing establishment of an infection [357]. Indeed, here we note that depletion of RIP3, 
which we show to be a positive regulator of autophagy, enhances VSV infection in IECs, a virus 
whose replication can be restricted by autophagy [358]. In contrast, autophagy is conducive to 
enterovirus replication, possibly through the provision of membranes for the assembly of viral 
replication complexes. Whether flux through the autophagic pathway is necessary or autophagic 
initiation alone is sufficient to promote CVB replication remains unclear. Here, our data suggest 
that a post-initiation and RIP3-regulated step of autophagic flux may be involved in the 
regulation of CVB infection in polarized IECs, consistent with the notion that complete 
autophagic flux promotes CVB replication. 
Recently it was reported that exogenously expressed RIP3 and p62 associated in 293T 
cells, a line that does not express any endogenous RIP3 [347]. Here, we show that endogenous 
RIP3 exists in complex with endogenous p62 in IECs under resting conditions. As p62 is 
necessary for selective autophagy through its role in binding to both the autophagic membrane 
associated protein LC3B and cellular components destined for degradation [359], it is likely that 
the endogenous association of RIP3 with p62 serves to recruit RIP3 to the inside of APs, where it 
acts to promote flux. Consistent with this, we found that RIP3 is degraded during autophagy, 
likely due to its localization within the AP.  
We propose that RIP3 may be a tissue-specific regulator of autophagy. It is known that 
autophagy is an especially important pathway in IECs for maintaining intestinal homeostasis. 
Genome wide association studies have identified a role for autophagy related genes in 
inflammatory bowel disease [360] and autophagy is known to be important for the maintenance 
of the intestinal epithelium as a barrier against intestinal pathogens [361]. Thus, RIP3 may 
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function as an IEC-specific regulator of autophagy. In support of this, we found that ectopic 
expression of RIP3 in HeLa cells had little impact on CVB replication. Additionally, autophagy 
is known to play a key role in embryonic development and mice deficient in various genes 
required for autophagy display embryonic lethality [362]. As RIP3 deficient mice do not exhibit 
such defects [363], and RIP3 is expressed in tissue-specific patterns [364], it is unlikely that 
RIP3 is globally required for autophagy.   
The function of RIP3 in necrosis is conserved between mice and humans. However, 
residue Q430 in human RIP3, which is targeted by CVB 3Cpro, is not conserved in mouse RIP3 
(Figure 16A). Interestingly, sequence comparisons of RIP3 from several primates revealed that 
RIP3 in Old World and New World monkeys contains a Histidine at position 430, whereas the 
evolution of a Glutamine at position 430 arose in the common ancestor of the apes. (Figure 
16A). Indeed, we found that neither African Green Monkey nor Colobus Monkey RIP3 
constructs were targeted by 3Cpro for cleavage (Figure 16B). The viral protease 3Cpro is well-
conserved among all enteroviruses. The ubiquity of these viruses suggests extensive co-evolution 
of enteroviruses with their hosts, perhaps made possible in part by their ability to take advantage 
of the newly evolved cleavage site in RIP3 of ancestral apes. Indeed, limiting necrotic cell death 
through cleavage of RIP3 at residue Q430 by 3Cpro could serve to lessen the damaging 
inflammatory effects of intestinal necrosis; such attenuations of pathogenic effects of infection 
are common in viral pathogens that are well-adapted to their hosts [365]. 
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Figure 16. RIP3 residue Q430 is conserved in the common ancestor of the apes. 
(A) Sequence alignments of RIP3 from the Homonidae family (Homo sapiens and Pan troglodytes), the Old World 
Monkeys (African green monkey and Colobus monkey), the New World Monkeys (Marmoset) and Mus musculus 
are shown. Red box indicates position Q430 in Homo sapiens and aligned positions in other sequences. Sequence 
alignments were made using SNAP [366] (B) 293T cells ectopically expressing Flag-tagged human, African green 
monkey (AGM), or Colobus monkey RIP3 with Myc-tagged WT or C147A CVB 3Cpro were immunoblotted for 
Flag (top) or Myc (bottom). Grey arrow indicates RIP3 cleavage fragment. 
  
Here, we show that RIP3 serves as a specific pro-viral regulator of CVB replication in 
polarized IECs via its role in the regulation of autophagy. Although the polarized intestinal 
epithelium is likely to be the primary cell type targeted by CVB during host invasion, the 
mechanisms by which CVB establishes its infection in these cells have remained elusive. Our 
findings thus advance our understanding of intestinal epithelial cell pathways that specifically 
facilitate CVB replication and the pathways used by the virus to attenuate these defenses and 
promote intestinal infection.  
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4.0  CONCLUSIONS 
Through the work presented here, we have identified two independent host cell pathways that are 
modified by CVB infection. CVB, a virus that contains only 7 kB of genetic material, must use 
this limited genetic real estate efficiently in order to effectively replicate in and transmit from a 
host. Replication and transmission is thereby accomplished through extensive remodeling of host 
cell pathways by a limited number of viral proteins. The long evolutionary history of 
enteroviruses with their human hosts has resulted in a finely tuned set of interactions between 
virus and host whose study is both fascinating and useful. Here, we have uncovered previously 
unappreciated roles of two proteins, Unc93b and RIP3, in apoptosis and autophagy, respectively. 
Additionally, we have furthered the understanding of CVB pathogenesis by delineating the ways 
in which CVB infection alters these proteins. This work underlines the importance of viruses as 
tools for probing the functions of the host cell as well as emphasizing the need for understanding 
the ways in which a host and pathogen interact in order to fully understand the pathogenesis of 
an infectious agent. 
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4.1 UNC93B AND CELL DEATH 
In Chapter 2, we presented work that significantly contributes to the field of Unc93b research. 
We have shown that Unc93b, which previously was known only to serve as an accessory to TLR 
trafficking, also has a role in the induction of apoptotic cell death (Figure 4). As the ability of 
Unc93b to induce cell death was dependent on its ability to leave the ER (Figure 4), it is 
possible that Unc93b serves to traffic some component of apoptotic cell death machinery. 
Additionally, we show that Unc93b is targeted for proteolysis by both CVB and host cell 
caspases in the same 10 amino acid region (Figures 5, 6). Though we find that these cleavage 
events do not alter the role of Unc93b in cell death or in TLR trafficking (Figures 6, 7, 8), this 
work provides a foundation for future studies of Unc93b function, and is the first report to our 
knowledge of any proteolytic processing of Unc93b. 
4.2 RIP3 AND CVB INFECTION 
In Chapter 3, we examine the role of RIP3 in CVB infection. RIP3 was identified in an RNAi 
screen in IECs as a gene product that facilitates CVB infection (Figure 9). Previously known to 
be involved in necroptotic signaling and inflammasome activation, here we provide evidence that 
RIP3 also positively regulates autophagy in IECs (Figure 11), and suggest that it is this role that 
facilitates CVB infection (Figure 10). Further, we show that during CVB infection, 3Cpro targets 
RIP3 for cleavage (Figure 13). This cleavage event inhibits the role of RIP3 in necroptotic 
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signaling (Figure 14). Interestingly, the amino acid residue targeted by 3Cpro for proteolytic 
processing is conserved among the great apes, but is not conserved in old world or new world 
monkeys (Figure 16). Taken together, this work greatly advances the knowledge of RIP3, 
provides a connection between necroptosis and autophagy, and identifies an IEC-specific factor 
necessary for CVB replication. 
4.3 CONCLUDING REMARKS 
In conclusion, the work presented here has identified two proteins, Unc93b and RIP3, that are 
both targeted for cleavage during CVB infection by the virally-encoded protease 3Cpro. In 
investigating the roles of these proteins in CVB infection, we discovered previously 
unappreciated aspects of the basic biology of each of them—that Unc93b is involved in apoptotic 
signaling and that RIP3 positively regulates autophagy in IECs. Understanding the ways in 
which innate immune signaling, cell death, and autophagy relate to one another in the context of 
viral infection is key to further developing the field of host-pathogen interaction. Here, we 
contribute to the understanding of each of these pathways, which have deep and pervasive 
impacts on diverse aspects of human health. 
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5.0  MATERIALS AND METHODS 
Cells and Viruses. 
Human kidney 293T cells stably expressing Flag-tagged TLR3 (293T-TLR3) were kindly 
provided by Dr. Saumendra Sarkar (University of Pittsburgh). HT29 cells stably expressing an 
shRNA vector targeting RIP3 and HeLa cells stably expressing a tetracycline-inducible RIP3 
construct (HeLa-RIP3TetOn) were kindly provided by Dr. Xiaodong Wang (National Institute of 
Biological Sciences, Beijing), as previously described [207, 258]. HeLa-RIP3TetOn cells were 
treated with 1 ug/ml Tetracycline to induce RIP3 expression.  
Human kidney 293T cells, 293T-TLR3, HeLa-RIP3TetOn, and human osteosarcoma 
U2OS cells were cultured in DMEM supplemented to contain 10% FBS. HeLa 7B cells were 
cultured in MEM supplemented with 5% FBS and nonessential amino acids. Human colorectal 
adenocarcinoma Caco-2 cells (ATCC HTB-37) were cultured in minimal essential media (MEM) 
supplemented with 20% fetal bovine serum (FBS), sodium pyruvate, and nonessential amino 
acids. Human colorectal adenocarcinoma HT29 cells (ATCC HTB-38) were cultured in 
McCoy’s 5A (modified) media supplemented with 10% FBS. 
Media for all cell lines was supplemented with penicillin-streptomycin and all cells were 
grown at 37°C, 5% CO2.  
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 Experiments were performed with CVB3-RD or VSV-GFP (Indiana), as previously 
described [56]. Neutral red-labeled CVB3-RD was prepared as previously described [58]. For 
time courses of infection, CVB was pre-adsorbed to cells for 1 hr at 16oC to synchronize 
infection. 
  
Plasmids. 
WT Unc93b constructs were constructed by amplification of Unc93B1 pCR4-TOPO purchased 
from Harvard PlasmID (clone ID: HsCD00341813) with primers encoding a C-terminal Myc tag 
followed by insertion into the HindIII and KpnI sites of eGFP-C2 (NT-GFP, CT-Myc construct) 
or pcDNA3.1(+) (CT-Myc construct). Truncated Unc93b constructs were constructed by 
amplification of Unc93B1 pCR4-TOPO using primers encoding a C-terminal Myc tag and 
beginning amplification at residues 18 or 28 for Δ17 or Δ27, respectively, followed by insertion 
into the HindIII and KpnI sites of pcDNA3.1(+). Unc93bΔ30 was constructed by amplification 
of Unc93B1 pCR4-TOPO using primers encoding a C-terminal Myc tag and beginning 
amplification at residue 31 followed by insertion into the HindII and KpnI sites of eGFP-C2.  
Point mutations producing alanine substitutions in residues Q17 and D27 or an arginine 
substitution in residue H412 were generated by splice overlap extension, as previously described 
[367]. NT-GFP, CT-Myc Unc93bQ17A or Unc93bD27A were then constructed by amplification 
using primers encoding a C-terminal Myc tag followed by insertion in the HindIII and KpnI sites 
of eGFP-C2. CT-Myc Unc93bH412R was then constructed by amplification using primers 
encoding a C-terminal Myc tag followed by insertion into the HindIII and KpnI sites of 
pcDNA3.1(+).  
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 GFP tagged RIP3 was constructed by amplification of RIP3 cDNA followed by insertion 
into the HindIII/KpnI sites of eGFP-C2 (Clontech). Flag-tagged RIP3 was constructed by 
amplification of RIP3 cDNA using primers encoding an N-terminal Flag tag followed by 
insertion into the HindIII/XhoI sites of pcDNA3.1(+). Point mutations in RIP3 to produce 
alanine substitutions at residue K50 was generated using splice overlap extension mutagenesis, 
as previously described [367], whereas those at Q134 and Q430 were generated using Stratagene 
Quikchange mutagenesis according to manufacturer’s protocol. GFP tagged RIP3NT or RIP3CT 
were generated by amplification of RIP3 cDNA using primers amplifying bases encoding for 
residues one through 430 or 431 through 518, respectively, followed by insertion into the 
HindIII/KpnI or EcoRI/BamHI sites of peGFP-C2, respectively.  
 HA-tagged RIP1 was constructed by amplification of purchased RIP1 cDNA with 
primers encoding an N-terminal HA tag followed by insertion into the XhoI/HindIII sites of 
pcDNA3.1(+).  
 GFP tagged and Myc-tagged CVB-3Cpro and CVB-3CproC147A were generated as 
previously described [174, 180].  
 TRIF constructs were generated as previously described [174]; NT-TRIF contains 
residues 1-359, whereas CT-TRIF contains residues 360-712.  
 Venus VSV-G was purchased from Addgene (plasmid 11914, deposited by Dr. Jennifer 
Lippincott-Schwartz and described previously [335]). 
 RFP-tagged LC3B was purchased from Addgene (plasmid 21075, deposited by Dr. 
Tamotsu Yoshimori and described previously [368]). 
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 Non-human primate RIP3 cDNA and primate RIP3 sequences were kindly provided by 
Dr. Harmit Malik (Fred Hutchinson Cancer Research Center). Flag-tagged non-human primate 
RIP3 constructs were generated through amplification of these cDNAs using primers encoding 
an N-terminal flag tag followed by insertion into the HindIII and XhoI sites of pcDNA3.1(+).  
 
Reagents. 
Necrostatin-1 was purchased from Calbiochem and used at a concentration of 5μM. Bafilomycin 
A1 was purchased from Sigma and used at a concentration of 100 nM. Poly(I:C) was purchased 
from GE Lifesciences. Poly(I:C) was used at 1μg/mL. zVAD-fmk was purchased from 
Calbiochem (Caspase Inhibitor VI), Invivogen (tlrl-vad), or ApexBio (A1902) and was used at 
100 μM. TNFα was purchased from Sigma (H8916) and was used at 50 ng/mL. JSH-23 was 
purchased from Calbiochem (481408) and was used at 7.1 μM. Staurosporine was purchased 
from Sigma (S6942) and was used at 8 μM. 
 Plasmid transfections were performed with Xtreme Gene HP or Xtreme Gene 9 (Roche) 
and siRNA transfections were performed with Dharmafect-1 (GE Dharmacon) according to 
manufacturer’s protocols 
 Buffers: Luciferase Cell Culture Lysis Reagent (CCLR; Promega; 25 mM Tris-phosphate 
pH 7.8, 2mM DTT, 2mM 1,2-diaminocyclohexane-N,N,N’,N’-tetraacetic acid, 10% glycerol, 
1% Triton X-100) was purchased from Promega. RIPA Buffer (50 mM Tris-HCl (pH 7.4), 1% 
NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1mM EDTA, 1 mM phenylmethanesulfonyl 
fluoride, protease inhibitor tablets (Pierce)),  EBC Buffer (50 mM Tris, 120 mM Nacl, 0.5% NP-
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40, ph 8.0, protease inhibitor tablets (Roche)), and NETN Buffer (900 mM NaCl, 1 mM EDTA, 
20 mM Tris, 0.5% NP-40, pH 8.0), were all made in house. 
 
Antibodies. 
Mouse monoclonal antibody directed against enterovirus VP1 (NCL-ENTERO) was purchased 
from Novocastra Laboratories. Rabbit monoclonal antibody against PARP (46D11) was 
purchased from Cell Signaling Technology. Rabbit polyclonal antibody directed against RIP3 
was purchased from Imgenex (Novus). Rabbit polyclonal anti-LC3B and mouse monoclonal 
antibodies against p62 and HMGB1 were purchased from Abcam. Rabbit polyclonal or mouse 
monoclonal antibodies against GAPDH, GFP, and Myc were purchased from Santa Cruz. Mouse 
monoclonal antibody against Flag (M2) was purchased from Sigma and mouse monoclonal 
antibody against RIP1 was purchased from BD-Biosciences. Alexa-Fluor conjugated secondary 
antibodies were purchased from Invitrogen, HRP-conjugated secondary antibodies were 
purchased from Santa Cruz and IRDye conjugated secondary antibodies were purchased from 
LI-COR Biosciences.  
 
siRNAs. 
siRNA targeting RIP3 was purchased from Sigma (sequence 5’-3’: 
GGAAUGCCUACCAAAAACU). Control siRNAs were purchased from Ambion (AM4621) or 
Sigma (SIC-001). 
 
RNAi Screen. 
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Using the Ambion druggable genome siRNA library (~7000 genes), four siRNAs targeted to a 
single gene product were arrayed in pairs in duplicate collagen-coated 384-well plates and 
reverse transfected into Caco-2 cells with Lipofectamine 2000 transfection reagent (Life 
Technologies) followed by infection with CVB (2 PFU/cell) for 6 hours. After fixation, infection 
levels were assessed by immunofluorescence staining with a primary antibody directed against 
VP1 and a fluorescein isothiocyanate (FITC) conjugated secondary antibody and cell number 
was assessed through the nuclear stain DAPI. The percentage of infected cells was determined 
through automated image acquisition (ImageXpressMicro Microscope) and analysis 
(MetaXpress). Percentage of cells (DAPI+) infected with CVB (VP1+) were log transformed and 
used to calculate the mean and interquartile ranges and these data were used to calculate robust Z 
scores. Genes associated with cell toxicity (robust Z score for DAPI+ ≤ -2) were eliminated, then 
genes were selected for which wells with identical siRNAs inhibited infection in duplicate assays 
(with robust Z-scores ≥ 2.0 or - ≤ 2.0), or for which inhibition (with Z-scores ≥ 1.7 or ≤ -1.7) was 
seen in at least 3 of 4 wells   These candidate genes were then subjected to a secondary screen in 
which 4 siRNAs, different from those used for the primary screen, were plated individually in 
duplicate 384-well plates. Transfection, infection, imaging, and image analysis were performed 
as in the primary screen. Genes whose targeting by at least one siRNA resulted in a robust Z 
score of ≥ 1.7 or ≤ -1.7 were considered hits. 
 
Neutral Red CVB Entry Assay. 
Confluent cell monolayers were grown in 8-well chamber slides (BD Biosciences) and then 
incubated with neutral red-labeled CVB3-RD (described above) (MOI=10) for one hour at 16°C 
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in semi-dark conditions in McCoy’s 5A (modified) media supplemented with 20 mM HEPES. 
Monolayers were then washed in PBS and fresh media was added. Monolayers were incubated at 
37°C, 5% CO2 and illuminated for 20 minutes on a light box at 0 or 120 minutes p.i., or kept in 
semi-dark conditions. 16-18 hours post-infection, infection levels were assessed by 
immunofluorescence microscropy to detect VP1 as described above.  
 
Immunoblotting 
Confluent monolayers were grown in 24-well plates. Monolayers were lysed in in Luciferase 
Cell Culture Lysis Reagent (Chapter 2) or RIPA Buffer (Chapter 3 and Figure 4e). Lysates were 
briefly sonicated and nonsoluble cell debris was removed through centrifugation.  Protein lysates 
in SDS containing sample buffer (Boston BioProducts) were heated at 95°C for 10 minutes, then 
electrophoresed in polyacrylamide gradient gels (4-20% or 10-20%, Bio-Rad). Protein was 
transferred onto nitrocellulose membranes and probed with indicated primary antibodies in 5% 
non-fat dry milk and the appropriate secondary antibodies conjugated to horseradish peroxidase 
(HRP, Santa Cruz) or infrared dyes (Li-Cor) and protein was detected using chemiluminescent 
HRP substrates (Pierce) or by the Odyssey CLx imaging system (Li-Cor).  
 
Immunoprecipitation Assay. 
Confluent monolayers were grown in 6-well plates. Monolayers were lysed in EBC Buffer. 
Nonsoluble cell debris was removed through centrifugation. A portion of the lysate was then 
incubated with primary antibody overnight at 4°C (for p62 immunoprecipitations) or 90 minutes 
at 4°C (for GFP immunoprecipitations), followed by incubation with Protein G agarose beads 
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(Pierce) for 60-90 minutes at 4°C. Protein G beads were then washed with NETN Buffer. Protein 
was eluted off beads in SDS containing sample buffer (Boston BioProducts) and heated at 95°C 
for 10 minutes followed by electrophoresis and immunoblotting as described above. 
 
qRT-PCR. 
Confluent monolayers were grown in 24-well plates, then total RNA was isolated using TRI 
Reagent (Sigma) according to manufacturer’s protocol. Any contaminating genomic DNA was 
removed using RNase-free DNaseI (Qiagen), followed by ethanol precipitation of RNA. cDNA 
was produced from isolated RNA using an iScript cDNA synthesis kit (Bio-Rad) according to 
manufacturer’s protocol. cDNA levels were quantified using quantitative PCR with iQ SYBR 
Green Supermix (Bio-Rad) in an Applied Biosystems StepOnePlus Real-Time PCR system. 
RNA levels were normalized to an internal standard (actin) and normalized to the indicated 
control. Primers to detect actin, CVB, and VSV have been described previously [369]. Primers to 
detect RIP3 were as follows: (Forward: 5’-TGCTGGAAGAGAAGTTGAGTTG; Reverse: 5’-
CTGTTGCACACTGCTTCGTACAC) 
 
Reporter Gene Assays. 
Cells were co-transfected with a plasmid containing a renilla luciferase gene (pRL-null, 
Promega) and a plasmid containing a firefly luciferase gene under the control of an NF-κB 
responsive promoter (kindly provided by Saumendra Sarkar, University of Pittsburgh), or an 
IFNβ promoter (p125-luc) at a ratio of 1:30, renilla:firefly. Levels of firefly and renilla luciferase 
were quantified using the Dual-Luciferase Reporter Assay System (Promega) according to 
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manufacturer’s protocol and a Synergy 2 luminescence plate reader (Bio-Tek). Firefly luciferase 
levels were normalized to renilla luciferase levels. 
 
Flow Cytometry. 
Cells were grown to confluence in 24-well plates, then stained with Annexin V and Propidium 
Iodide (PI) or PI alone using the AlexaFluor488 Annexin V/Dead Cell Apoptosis Kit 
(Invitrogen) according to the manufacturer’s protocol and analyzed using a MACSQuant 
Analyzer (Miltenyi). Data analysis was performed using FlowJo software. 
 
Microscopy. 
 Confluent monolayers grown in 8-well chamber slides (BD Biosciences) were fixed and 
permeabilized with an ice-cold mixture of 3:1 methanol:acetone or 4% paraformaldehyde 
followed by 0.1% Triton X-100. Cells were incubated with the indicated primary antibodies for 1 
hour at RT, washed in PBS, then incubated in appropriate AlexaFluor-conjugated secondary 
antibodies for 30 minutes at RT, washed in PBS, and mounted in Vectashield containing DAPI 
(Vector Labs). Images were captured using a FV1000 confocal laser scanning microscope 
(Olympus). Image analysis was performed using Imaris (Bitplane) or ImageJ and contrasted and 
merged using Phostoshop (Adobe). For differential interference contrast (DIC) microscopy, 
confluent monolayers were grown in 35 mm glass-bottomed dishes (Mat Tek) and images were 
captured from living cells using IX81 or IX83 inverted microscopes (Olympus). Transmission 
electron microscopy was performed as described [369]. For measurements of amphisome size 
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and number by TEM, at least 40 individual amphisomes were measured using ImageJ from at 
least 10 unique cells. 
 
Virus Titration. 
Intracellular virus was prepared for titration by three successive freeze-thaw cycles. To titrate 
virus, HeLa 7B cells were cultured to confluence in 12-well plates. Cells were incubated for 1 
hour at room temperature with serially diluted samples followed by overlay of cell culture media 
containing 0.4% agarose. 48 hours post-infection agarose overlays were removed and plaques 
were visualized through fixation and staining with a solution of ethanol and crystal violet.  
 
Cell Viability Assays. 
Cells to be analyzed by Cell Titer Glo Assay were grown to confluency in 96-well plates, then 
mock- or staurosporine-treated. Cell Titer Glo Luminescent Cell Viability Assays (Promega) 
were performed as described in manufacturer’s protocol. 
 
Statistical Analysis. 
All statistical analysis was performed using GraphPad Prism. Students t-test or one-way 
ANOVA were performed as appropriate.  * indicates p<0.05. ** indicates p<0.01. *** indicates 
p<0.001. **** indicates p<0.0001. 
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APPENDIX A 
TABLE OF ABBREVIATIONS 
5’-ppp – 5’-triphosphate group 
AP – autophagosome 
AP2 – assembly protein 2 
AP4 – assembly protein 4 
ATCC – American type culture collection 
ATF3 – activating transcription factor 3 
ATF6 – activating transcription factor 6 
Atg9 – autophagosome-related 9 
BafA1 – bafilomycin-A1 
Bcl-2 – B-cell lymphoma 2 
Bcl-XL – B-cell lymphoma extra large 
C-terminus – carboxy terminus 
CAR – coxsackievirus and adenovirus receptor 
CCLR – cell culture lysis reagent 
cDNA – complementary DNA 
cFLIP – cellular FLICE-inhibitory protein 
cFLIPL – cFLIP long isoform 
cFLIPs – cFLIP short isoform 
CHOP – C/EBP homologous protein 
cIAP – cellular inhibitor of apoptosis 
CMV – cytomegalovirus 
CNS – central nervous system 
COPII – coat protein II 
CpG – unmethylated deoxycytidylate-phosphate-deoxyguanylate 
CVB – coxsackievirus B3 
CYLD – cylindromatosis 
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DAF – decay accelerating factor 
DAI – DNA-dependent activator of IRFs 
DAMP – damage associated molecular patterns 
DAPI – 4’,6-diamidino-2-phenylindole 
DAVID – the database for annotation, visualization and integrated discovery 
DC – dendritic cell 
DIC – differential interference contrast 
DMEM – dulbecco’s modified eagle’s medium 
DNA – deoxyribonucleic acid 
Drp1 – dynamin-related protein 1 
dsRNA – double stranded RNA 
ECHO – enteric cytopathic human orphan 
eGFP – enhanced GFP 
eIF-4G – eukaryotic initiation factor 4G 
ER – endoplasmic reticulum 
ERGIC – ER-Golgi intermediate compartment 
FADD – Fas-associated protein with Death Domain 
FAK – focal adhesion kinase 
FBS – fetal bovine serum 
FLICE – FADD-like ICE 
FSC – forward-scatter light 
GAPDH – glyceraldehyde 3-phosphate dehydrogenase 
GFP – green fluorescent protein 
GI – gastrointestinal  
GTP – guanosine triphosphate 
HBMEC – human brain microvascular endothelial cells 
HMGB1 – high-mobility group protein B1 
HSE – herpes simplex encephalitis 
HSV-1 – herpes simplex virus 1 
ICE – interleukin-1β-converting enzyme 
ICP6 – infected cell protein 6 
IEC – intestinal epithelial cell 
IFN – interferon 
IFNAR – interferon α/β receptor 
IGTP – interferon γ induced GTP-ase 
IL-12p40 – interleukin 12p40 
IL-6 – interleukin 6 
IRE1 – inositol requiring enzyme 1 
IRES – internal ribosomal entry site 
IRF – interferon regulatory factor 
ISG – interferon stimulatory gene 
JNK – c-Jun N-terminal kinase 
kB – kilobase  
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kD – kiloDalton 
LC3B – light chain 3 B 
LGP2 – laboratory of genetics and physiology 2 
LPS – lipopolysaccharide  
MAM – mitochondria-associated membrane 
MAVS – mitochondrial antiviral signaling 
mCMV – murine CMV 
MDA5 – melanoma differentiation associated 5 
MEFs – murine embryonic fibroblast 
MEM – minimal essential media 
MLKL – mixed lineage kinase domain-like 
MOI – multiplicity of infection 
mRFP – modified RFP 
N-terminus – amino terminus 
Nec-1 – necrostatin-1 
NF-κB – nuclear factor kappa light chain enchancer of activated B cells 
NIAID – National Institute of Allergy and Infectious Disease 
NR – neutral red 
ns – non-specific 
p.i. – post infection 
p38MAPK – p38 mitogen-activated protein kinase 
PABP – poly(A) binding protein 
PAMP – pathogen associated molecular pattern 
PARP – poly ADP ribose polymerase 
PCR – polymerase chain reaction 
pDC – plasmacytoid DC 
PERK – PKR-like ER kinase 
PI – propidium iodide 
PI3K – phosphoinositide 3-kinase 
PKR – protein kinase R 
Poly(I:C) – polyinosinic:polycytidylic acid 
PRR – pattern recognition receptor 
RHIM – RIP homotypic interaction motif 
RIG-I – retinoic acid-inducible gene 1 
RIP1 – receptor interacting protein kinase 1 
RIP3 – receptor interacting protein kinase 3 
RIPA – radioimmunoprecipitation assay 
RLR – RIG-I like receptor 
RNA – ribonucleic acid 
RNAi – RNA interference 
ROS – reactive oxygen species 
RP – retinitis pigmentosa 
RT-qPCR – reverse transcription quantitative PCR 
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SAPK – stress activated protein kinase 
SCID – severe combined immunodeficiency 
SDS-PAGE – sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
Ser – serine  
shRNA – small hairpin RNA 
siRNA – small interfering RNA 
SLE – systemic lupus erythematosus 
SNAP – scalable nucleotide alignment program 
SNAP – soluble NSF attachment protein 
SNARE – SNAP receptor 
SNP – single nucleotide polymorphism  
SQSTM1 – sequestosome 1 
SS – serum starve 
SSC – side-scattered light 
ssRNA – single stranded RNA 
TBP – TATA binding protein 
TEM – transmission electron microscopy 
TFIIIC – transcription factor for polymerase III C 
Thr - threonine 
TLR – toll-like receptor 
TNFR1 – TNFα receptor 1 
TNFα – tumor necrosis factor α 
TRADD – TNFR1 associated death domain protein 
TRAF2 – TNFR1 associated factor 2 
TRIF – TIR-domain-containing adapter-inducing IFNβ 
TRPM7 – transient receptor potential cation channel, subfamily M, member 7 
Ubl – ubiquitin-like 
ULK – unc-51 like kinase  
UPR – unfolded protein response 
VAMP8 – vesicle-associated membrane protein 8 
vIRA – viral inhibitor of RIP activation 
VP1 – viral protein 1 
VP2 – viral protein 2 
VP4 – viral protein 4 
VPg – viral protein genome linked 
VRCs – viral replication complexes 
vRNA – viral RNA 
VSV-G – vesicular stomatitis virus glycoprotein 
VV – vaccinia virus 
WT – wild type
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Appendix B 1. RIP3 is required for autophagic flux in intestinal epithelial cells. 
(A) Transmission electron micrographs from Figure 11A were quantified for number of nonviable cells. At least 13 
individual cells were observed per condition. (B) Immunofluorescence images from Figure 11C were quantified for 
number of p62 punctae using Imaris. At least 28 individual cells were quantified per condition. (C) Transmission 
electron micrographs of WT HT29 or HT29shRIP3 cells treated with BafA1 are shown, black arrows denote 
amphisomes, hatched box denotes zoomed image shown above. (D) HT29 cells transfected with siRNA targeting 
RIP3 or a control scrambled sequence in nutrient rich or depleted (SS) conditions for 12 hours then immunoblotted 
for LC3B (top) and GAPDH (bottom). Densitometry was performed and is shown below. Control lysates (nutrient 
rich) are the same lysates immunoblotted in Figure 11B. (E) WT HT29 or HT29shRIP3 cells were infected with 
CVB (5PFU/cell) for 7 hours then immunoblotted for LC3B. 
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